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Abstract	  
Tissue	  vascularization	  and	  integration	  with	  host	  circulation	  remains	  a	  key	  barrier	  
to	  the	  successful	  translation	  of	  engineered	  tissues	  into	  clinically	  relevant	  therapies.	  
Current	  efforts	  to	  implant	  large	  engineered	  structures	  are	  limited	  by	  insufficient	  delivery	  
of	  oxygen	  and	  nutrients,	  and	  waste	  removal.	  	  Work	  presented	  in	  this	  thesis	  focus	  on	  the	  
use	  of	  a	  naturally	  derived	  nanofiber	  for	  improving	  molecular	  interactions	  between	  
vascular	  endothelial	  cells	  and	  smooth	  muscle	  cells	  for	  application	  to	  vascular	  
bioengineering.	  We	  hypothesize	  optimization	  of	  instructive	  interactions	  between	  
vascular	  cell	  types	  can	  improve	  formation	  of	  microtissue	  spheroids	  for	  application	  to	  
vascular	  bioengineering.	  Toward	  this	  goal,	  I	  use	  shortened	  poly-­‐N-­‐acetyl	  glucosamine	  
(sNAG)	  nanofibers	  to	  facilitate	  co-­‐assembly	  of	  pre-­‐vascularized	  network	  formation	  
within	  microtissue	  spheroids.	  To	  gain	  initial	  insights	  into	  the	  potential	  use	  of	  sNAG	  as	  an	  
instructive	  biomaterial	  for	  vascular	  tissue	  regeneration	  applications,	  UCB-­‐EPCs,	  ADSC-­‐
VSMCs,	  and	  AoAFs	  were	  co-­‐cultured	  in	  cell-­‐aggregates	  in	  the	  presence	  of	  sNAG	  or	  other	  
known	  effectors	  of	  vascular	  assembly.	  Immunofluorescence	  analysis	  by	  confocal	  
microscopy	  revealed	  a	  strong	  angiogenic	  effect	  on	  EC-­‐only	  monocultures,	  which	  
resulted	  in	  EC	  sprout	  formation,	  and	  remodeling	  in	  2D	  Matrigel	  assays.	  When	  grown	  in	  
3D,	  sNAG	  nanofibers	  induced	  UCB-­‐EPCs	  migration	  and	  increased	  levels	  of	  hPECAM-­‐1	  
expression,	  indicative	  of	  a	  fully	  differentiated	  EC	  phenotype.	  Heterotypic	  cell	  cultures	  
show	  that	  sNAG	  nanofibers	  elicit	  synthesis	  of	  proteins	  associated	  with	  vascular	  wall	  
assembly	  and	  stabilization.	  An	  interesting	  finding	  of	  these	  analyses	  was	  that	  expression	  
of	  collagen	  type-­‐4	  was	  significantly	  increased	  in	  our	  sNAG	  treated	  microtissue	  spheroids.	  
This	  increase	  was	  greatest	  in	  areas	  of	  heterotypic	  cell	  association,	  highlighting	  the	  
importance	  of	  cross	  talk	  between	  EPC-­‐ECs	  and	  ADSC-­‐VSMCs	  in	  stimulating	  synthesis	  of	  
vascular	  wall	  components.	  Collectively,	  our	  preliminary	  studies	  suggest	  that	  sNAG	  
nanofibers	  may	  provide	  an	  instructive,	  biocompatible	  matrix	  for	  assembly	  of	  
prevascularized	  microtissue	  spheroids.	  	   	  
BACKGROUND	  
Cardiovascular	  disease	  (CVD)	  is	  the	  leading	  cause	  of	  morbidity	  and	  mortality	  
worldwide.	  [1,	  2]	  In	  the	  United	  States,	  cardiovascular	  diseases	  account	  for	  
approximately	  30%	  of	  all	  deaths,	  with	  CVD	  population	  constantly	  increasing.	  In	  2008	  
alone,	  86.2	  million	  Americans	  were	  living	  with	  some	  form	  of	  CVD,	  and	  this	  number	  is	  
projected	  to	  grow	  to	  40.5%	  of	  the	  American	  population	  by	  the	  year	  2030.	  
Concomitantly,	  the	  financial	  burden	  of	  disease	  is	  also	  projected	  to	  rise,	  from	  present	  
estimates	  of	  $300	  billion	  to	  $800	  billion.	  [3]	  On	  a	  global	  scale,	  CVD	  is	  responsible	  for	  
60%	  of	  deaths,	  and	  will	  become	  increasingly	  important	  as	  global	  obesity	  and	  
malnutrition	  continue	  to	  rise.	  Importantly,	  CVD	  is	  responsible	  for	  80%	  of	  non-­‐
communicable	  disease	  in	  low	  and	  middle-­‐income	  countries,	  with	  grave	  social	  and	  
economic	  consequences.	  	  
Unfortunately,	  despite	  this	  epidemic	  of	  increasing	  amounts	  of	  CVD,	  the	  
myocardium	  has	  very	  limited	  capacity	  to	  repair	  itself	  following	  injury	  compared	  to	  other	  
tissues.	  Two	  distinct	  cardiac	  pathologies	  that	  lead	  to	  coronary	  heart	  disease	  are	  
myocardial	  infarction	  (MI)	  and	  diabetic	  cardiomyopathy	  (DCM).	  In	  both	  cases,	  injury	  
occurs	  when	  a	  coronary	  artery	  becomes	  obstructed	  and	  tissue	  downstream	  of	  the	  
occlusion	  begins	  to	  die	  due	  to	  lack	  of	  oxygen.	  As	  a	  result,	  cardiac	  injury	  triggers	  a	  
pathologic	  adaptive	  cascade	  that	  occurs	  in	  three	  phases.	  The	  first	  is	  the	  inflammatory	  
phase,	  occurring	  hours	  to	  days	  after	  injury,	  in	  which	  cardiomyocyte	  death	  leads	  to	  the	  
release	  of	  chemokines	  and	  cytokines	  that	  recruit	  inflammatory	  cells	  to	  the	  site	  of	  injury.	  
This	  is	  followed	  by	  the	  proliferative	  phase	  (days	  to	  weeks),	  which	  is	  characterized	  by	  a	  
high	  degree	  of	  angiogenesis	  and	  mesenchymal	  cell	  recruitment	  to	  the	  site	  of	  injury.	  The	  
third	  and	  final	  phase	  is	  maturation	  of	  the	  scar	  tissue	  as	  the	  newly	  deposited	  ECM	  is	  
cross-­‐linked	  and	  the	  majority	  of	  fibroblasts	  and	  endothelial	  cells	  present	  in	  the	  previous	  
phases	  undergo	  apoptosis.	  Subsequent	  formation	  of	  scar	  tissue	  during	  the	  final	  stage	  of	  
the	  healing	  process	  results	  in	  maladaptive	  stiffening	  of	  the	  ventricular	  wall,	  which	  lacks	  
the	  contractile,	  mechanical,	  and	  electrical	  properties	  of	  the	  healthy	  myocardium.	  This	  
loss	  of	  function	  leads	  to	  further	  injury	  and	  subsequent	  progression	  into	  heart	  failure	  
(HF).	  	  
HF	  is	  a	  clinical	  syndrome	  characterized	  by	  systemic	  perfusion	  inadequate	  to	  meet	  
the	  body’s	  metabolic	  demands	  as	  a	  result	  of	  impaired	  cardiac	  pump	  function.	  
Contemporary	  treatments	  such	  as	  surgical,	  endovascular,	  and	  pharmacological	  
interventions	  are	  merely	  palliative	  in	  nature	  and	  do	  not	  adequately	  address	  the	  true	  
cause	  of	  heart	  failure	  –	  the	  loss	  of	  functional	  myocytes	  and	  supporting	  cardiac	  tissue.	  At	  
present,	  the	  only	  available	  treatment	  option	  for	  end-­‐stage	  HF	  is	  the	  Left	  Ventricular	  
Assist	  Device	  (LVAD);	  however,	  this	  device	  is	  generally	  intended	  for	  temporary	  use	  until	  
the	  patient	  can	  receive	  a	  full	  heart	  transplantation.	  As	  such,	  heart	  transplantation	  
remains	  the	  gold	  standard	  of	  care	  and	  the	  only	  curative	  therapy	  for	  replacing	  damaged	  
or	  diseased	  myocardium	  as	  a	  result	  of	  vascular	  insufficiency.	  Unfortunately,	  the	  current	  
availability	  of	  replacement	  hearts	  has	  become	  exceedingly	  limited	  due	  to	  a	  consistent	  
and	  growing	  gap	  between	  the	  number	  of	  patients	  waiting	  for	  organs	  and	  those	  
available.	  In	  1991,	  68%	  of	  patients	  on	  the	  waiting	  list	  received	  replacement	  hearts.[4]	  As	  
of	  2013,	  this	  number	  dropped	  to	  24%	  of	  patients	  on	  the	  waiting	  list	  [4],	  highlighting	  the	  
critical	  clinical	  need	  for	  innovative	  therapies	  that	  address	  the	  progression	  of	  
pathological	  remodeling	  and	  cell	  death,	  as	  well	  as	  to	  repair/regenerate	  the	  affected	  
areas.	  	  
	  
Cell-­‐Based	  Therapies	  for	  MI	  
The	  emerging	  of	  cardiovascular	  regenerative	  medicine	  may	  provide	  an	  
encouraging	  direction	  for	  future	  therapeutics,	  which	  focuses	  on	  replacing	  or	  
regenerating	  damaged	  myocardium,	  blood	  vessels,	  and	  microvasculature	  to	  restore	  or	  
establish	  normal	  cardiac	  function.[5,	  6]	  Besides	  cardiomyogenesis,	  cardioprotective	  
mechanisms,	  including	  anti-­‐fibrosis,	  anti-­‐inflammation,	  and	  neovascularization,	  have	  
been	  shown	  to	  play	  critical	  roles	  in	  cardiac	  repair	  following	  an	  ischemic	  event.	  [7]	  These	  
mechanisms	  represent	  promising	  therapeutic	  targets	  and	  can	  be	  exploited	  for	  
regenerative	  potential.	  This	  theory	  is	  supported	  by	  recent	  evidence	  that	  suggests	  
myocardial	  progenitor	  cells	  (MPCs)	  do	  not	  result	  in	  the	  formation	  of	  functional	  syncytia	  
and	  that	  their	  effects	  in	  post-­‐MI	  scarring	  might	  be	  mediated	  more	  by	  local	  paracrine	  
angiogenesis	  than	  by	  cardiomyocyte	  differentiation.	  [8,	  9]	  Hence,	  angiogenesis	  might	  
constitute	  an	  important	  mechanism	  of	  functional	  improvement	  not	  only	  among	  
modalities	  that	  specifically	  aim	  at	  angiogenesis	  (ie.	  for	  the	  treatment	  of	  myocardial	  
ischemia	  in	  the	  presence	  of	  viable	  heart	  muscle),	  but	  also	  among	  modalities	  aiming	  at	  
myogenesis	  to	  improve	  cardiac	  function	  after	  an	  MI	  (i.e.	  for	  the	  treatment	  of	  heart	  
failure	  in	  the	  presence	  of	  nonviable	  myocardium).	  [10-­‐12]	  Therefore,	  the	  ability	  to	  
induce	  angiogenesis	  or	  vasculogenesis	  via	  supplementation	  of	  vascular	  cell	  types	  could	  
provide	  an	  effective	  strategy	  for	  achieving	  post-­‐MI	  recovery.	  	  	  	  
Adult	  stem	  cells	  hold	  great	  potential	  to	  repair	  damaged	  heart	  tissue	  and	  can	  be	  
utilized	  as	  treatment	  to	  accelerate	  healing	  through	  potent	  paracrine	  signaling,	  with	  a	  
production	  of	  a	  multitude	  of	  proangiogenic	  factors,	  or	  by	  restoring	  tissue	  function	  by	  
direct	  contribution	  to	  neovascularization.	  Many	  clinicians	  prefer	  to	  utilize	  autologous	  
adult	  stem	  cells	  due	  to	  the	  relative	  low	  cost	  and	  safety	  as	  compared	  to	  embryonic	  stem	  
cell	  (ESC)	  or	  induced	  pluripotent	  stem	  cell	  (iPSC)	  use.	  Adult	  stem	  cells,	  unlike	  embryonic	  
stem	  cells,	  are	  not	  derived	  by	  sacrificing	  an	  embryo,	  thus	  avoiding	  many	  of	  the	  ethical	  
controversies	  involved	  in	  embryonic	  stem	  cell	  research.	  In	  fact,	  the	  therapeutic	  
application	  of	  adult	  stem	  cells	  is	  further	  along	  in	  clinical	  development	  than	  any	  other	  
stem	  cell	  approaches.	  [13]	  By	  contrast	  to	  ESCs	  or	  iPSCs,	  adult	  stem	  cells	  are	  partially	  
lineage-­‐committed	  and	  therefore	  have	  the	  capacity	  to	  give	  rise	  only	  to	  cells	  of	  a	  given	  
germ	  layer.	  In	  other	  words,	  they	  are	  multipotent,	  rather	  than	  pluripotent,	  which	  reduces	  
the	  likelihood	  of	  teratoma	  formation	  in	  vivo.	  [14]	  Although	  adult	  stem	  cells	  have	  a	  lower	  
renewal	  capability	  than	  ESCs	  and	  iPSCs,	  they	  have	  a	  greater	  proliferation	  rate	  than	  
terminally	  differentiated	  somatic	  cells,	  thus	  still	  benefiting	  regenerative	  medicine	  
approaches.	  
Several	  groups	  have	  demonstrated	  that	  adult	  stem	  cells	  are	  capable	  of	  
differentiating	  into	  a	  variety	  of	  essential	  vascular	  cell	  types,	  including	  endothelial	  cells,	  
as	  well	  as	  surrounding	  mural	  support	  cells	  required	  for	  vascular	  stability.	  Mural	  cells,	  
commonly	  referred	  to	  as	  vascular	  smooth	  muscle	  cells	  (SMCs)	  in	  larger	  vessels	  and	  
pericytes,	  in	  capillary	  beds	  are	  indispensable	  for	  the	  development	  of	  a	  mature	  and	  
durable	  vasculature.	  The	  importance	  of	  these	  cells	  is	  underscored	  by	  gene	  mutation	  
studies	  of	  mouse	  models	  where	  the	  absence	  of	  mural	  cells	  resulted	  in	  severe	  vascular	  
defects.	  [15-­‐17]	  Other	  in-­‐vivo	  studies	  have	  focused	  on	  the	  transplantation	  of	  harvested	  
progenitor	  cells,	  namely	  EPCs,	  into	  animal	  models	  of	  myocardial	  infarction	  or	  hindlimb	  
ischemia.	  In	  this	  context,	  hybrid	  cellular	  approaches	  have	  demonstrated	  greater	  success	  
than	  using	  single	  cell	  types.	  Co-­‐implantation	  of	  mouse	  mesenchymal	  precursor	  cells	  and	  
human	  EPCs	  sustained	  long	  term	  durability	  of	  engineered	  vascular	  networks	  while	  
implantation	  of	  ECs	  alone	  led	  to	  vessel	  regression	  within	  a	  week.	  Inclusion	  of	  mouse	  
embryonic	  fibroblasts	  in	  addition	  to	  human	  EPCs	  and	  mesenchymal	  cells	  enhanced	  the	  
viability	  of	  vascularized	  cardiac	  muscle	  patches,	  which	  integrated	  stably	  onto	  murine	  
myocardia.	  Thus,	  ECs	  and	  mural	  cells	  are	  both	  unequivocally	  necessary	  for	  the	  formation	  
of	  a	  functional	  vasculature.	  	  
	   Despite	  the	  impressive	  in	  vivo	  potential	  of	  adult	  stem	  cell-­‐based	  therapy,	  several	  
obstacles	  (e.g.,	  the	  difficulty	  of	  maintaining	  self-­‐renewal	  and	  poor	  survival	  due	  to	  
apoptosis	  and/or	  necrosis	  at	  the	  administration	  site)	  have	  been	  encountered.	  [18]	  The	  
primary	  limitation	  is	  the	  poor	  viability	  (low	  survival	  rates)	  of	  the	  transplanted	  adult	  stem	  
cells	  by	  anoikis	  in	  injured	  tissues.	  Anoikis	  is	  a	  form	  of	  programmed	  cell	  death	  that	  occurs	  
due	  to	  the	  loss	  of	  anchorage-­‐dependent	  attachment	  to	  the	  extracellular	  matrix	  (ECM).	  
[19,	  20]	  Because	  cell-­‐cell	  adhesion	  through	  the	  ECM	  plays	  an	  important	  role	  in	  cell	  
activities,	  proliferation,	  and	  survival,	  [21]	  a	  low	  propensity	  to	  adhere	  to	  the	  host	  cells	  
due	  to	  a	  loss	  of	  matrix	  anchorage	  may	  induce	  the	  death	  of	  the	  transplanted	  adult	  stem	  
cells.	  Although	  several	  ongoing	  studies	  are	  focused	  on	  improving	  adult	  stem	  cell	  
survival,	  no	  potential	  solutions	  have	  been	  suggested	  to	  solve	  the	  underlying	  problem	  of	  
weak	  adhesion.	  Therefore,	  enhancing	  the	  adhesion	  of	  the	  transplanted	  adult	  stem	  cells	  
through	  the	  inhibition	  of	  anoikis	  should	  improve	  the	  success	  of	  adult	  stem	  cell-­‐based	  
applications.	  [21]	  
	  
Biomaterials	  for	  Enhancing	  Stem	  Cell-­‐based	  Transplantation	  
Biomaterials	  made	  of	  both	  synthetic	  and	  natural	  polymers	  have	  gained	  much	  
attention	  in	  recent	  years	  due	  to	  their	  ability	  to	  modulate	  cell	  behavior.	  These	  materials	  
can	  be	  designed	  to	  create	  a	  well-­‐defined	  microenvironment	  in	  the	  tissue	  that	  can	  
specifically	  direct	  cell	  attachment	  and	  regenerative	  potential,	  and	  may	  be	  useful	  for	  
improving	  outcomes	  of	  stem	  cell-­‐based	  therapies.	  In	  particular,	  biomaterials	  can	  control	  
the	  release	  of	  growth	  factors	  and	  cytokines	  in	  a	  spatiotemporally	  regulated	  manner	  to	  
mimic	  endogenous	  signals	  that	  cells	  use	  for	  specific	  processes,	  and	  the	  concentration	  
can	  be	  tuned	  to	  levels	  effective	  for	  promoting	  the	  desired	  behavior.	  (MMP	  Sensitive)	  
The	  advantage	  of	  using	  biomaterials	  for	  stem-­‐cell	  delivery	  is	  that	  they	  provide	  initial	  
encapsulation	  of	  the	  donor	  cells	  and	  gradually	  precondition	  the	  cells	  to	  the	  local	  
biological	  environment	  for	  which	  they	  will	  be	  implanted.	  Furthermore,	  biomaterials	  
such	  as	  alginate-­‐based	  microcapsules	  can	  play	  an	  immunoprotective	  role	  by	  isolating	  
the	  donor	  cells	  from	  the	  host	  immune	  system	  and	  thus	  increase	  allogeneic	  cell	  
transplantation	  tolerance.	  [17,	  22]	  
Vascular	  progenitor	  cells	  can	  also	  be	  used	  to	  vascularize	  tissue	  patches	  or	  
construct	  vascular	  grafts.	  The	  ideal	  scaffolds	  for	  engineered	  tissue	  patches	  and	  vascular	  
grafts	  are	  usually	  composed	  of	  biomimetic	  ECM	  components.	  The	  presence	  of	  ECM	  can	  
encourage	  the	  maturation	  of	  newly	  formed	  blood	  vessels.	  The	  spatial	  complexity	  of	  ECM	  
creates	  defined	  topological	  cues	  that	  can	  regulate	  vascular	  specification	  and	  organize	  
vascular	  cells	  into	  tube-­‐like	  structures.[23]	  Physical	  contacts	  with	  the	  ECM	  also	  
modulate	  biophysical	  signals	  between	  the	  dynamic	  biological	  environment	  and	  the	  
donor	  cells,	  leading	  to	  better	  viability,	  engraftment	  and	  patency	  of	  vascularized	  tissue	  
patches	  or	  vascular	  grafts	  after	  implantation.	  A	  recent	  study	  by	  Xiong	  et	  al.	  reported	  
that	  the	  use	  of	  a	  porous	  fibrin	  biomatrix	  promoted	  significant	  engraftment	  of	  vascular	  
progenitor	  cells	  in	  a	  swine	  model	  of	  myocardial	  infraction.	  [24]	  Nevertheless,	  there	  are	  
only	  a	  few	  studies	  on	  biomaterial-­‐assisted	  generation	  and	  transplantation	  of	  
vascularized	  tissue	  patches	  or	  vascular	  grafts	  using	  progenitor	  cells.	  [17]	  The	  
vascularization	  process	  is	  typically	  too	  slow	  to	  maintain	  the	  viability	  of	  the	  therapeutic	  
cells	  of	  interest,	  and	  only	  tissues	  with	  low	  vascularization	  requirements,	  such	  as	  thin	  
skin	  tissue	  or	  cartilage,	  are	  currently	  available	  clinically.	  	  
Most	  of	  the	  current	  vascularization	  approaches	  have	  proven	  successful	  in	  
inducing	  blood	  vessel	  formation	  in	  vivo,	  but	  many	  of	  these	  blood	  vessels	  are	  not	  fully	  
functional	  (leaky	  or	  not	  connected	  to	  the	  host	  vasculature),	  and	  many	  regress	  over	  time.	  
Where	  some	  of	  these	  approaches	  have	  resulted	  in	  a	  functional,	  persistent	  blood	  vessel	  
network,	  the	  time	  required	  to	  achieve	  such	  functional	  vascularization	  is	  still	  too	  long	  to	  
be	  clinically	  relevant	  (several	  weeks	  for	  a	  millimeter	  sized	  implant).	  [25]	  Without	  an	  
immediate	  vascular	  supply,	  the	  majority	  of	  the	  therapeutic	  cells	  within	  the	  construct	  will	  
not	  survive.	  Going	  forward,	  much	  effort	  will	  need	  to	  be	  directed	  towards	  accelerating	  
the	  formation	  of	  a	  perfused	  (i.e.	  anastomosed)	  vascular	  network	  within	  the	  construct	  
and	  ensuring	  the	  new	  vasculature	  matures	  and	  persists.	  	  
	  
Modular	  Tissue	  Engineering	  
	   In	  order	  to	  enhance	  the	  function	  of	  bioengineered	  tissues,	  there	  is	  a	  need	  to	  
generate	  more	  complex	  structures	  with	  features	  such	  as	  developed	  and	  functional	  
microvasculature	  and	  tissue	  specific	  morphology.	  The	  emerging	  field	  known	  as	  modular	  
tissue	  engineering	  aims	  to	  accomplish	  these	  goals	  by	  fabricating	  microtissue	  building	  
blocks	  with	  intricate	  architectural	  features	  and	  using	  these	  modular	  units	  to	  engineer	  
biological	  tissues	  from	  the	  bottom	  up.	  These	  modules	  can	  be	  created	  in	  a	  number	  of	  
ways,	  such	  as	  through	  self-­‐assembled	  aggregation,	  [26]	  microfabrication	  of	  cell-­‐laden	  
hydrogels,	  [27]	  creation	  of	  cell	  sheets,	  [28]	  or	  direct	  printing	  of	  tissues.	  [29]	  Once	  
created,	  these	  modules	  can	  be	  assembled	  into	  larger	  tissues	  through	  a	  number	  of	  
methods	  such	  as	  random	  packing,	  [30]	  	  stacking	  of	  layers,	  [28,	  31]	  or	  directed	  assembly.	  
[32]	  By	  mimicking	  native	  microstructural	  functional	  units,	  bottom-­‐up	  approaches	  have	  
the	  ability	  to	  create	  more	  viable	  engineered	  tissues.[33,	  34]	  
	   The	  historical	  roots	  of	  the	  modular	  approach	  trace	  back	  to	  microencapsulation	  
techniques,	  such	  as	  encapsulating	  pancreatic	  islet	  cells	  in	  alginate	  gels	  for	  
transplantation	  in	  diabetic	  rats.[33]	  More	  recent	  studies	  focus	  on	  exploiting	  the	  intrinsic	  
vascularized	  nature	  of	  the	  modular	  approach	  by	  incorporating	  vascular	  supporting	  cells	  
(such	  as	  smooth	  muscle	  cells,	  (SMC),	  or	  mesenchymal	  stromal	  cells,	  (MSC))	  or	  
therapeutic	  cells	  of	  interest	  (cardiomyocytes,	  islets,	  or	  others),	  to	  be	  embedded	  inside	  
the	  modules.	  A	  significant	  advantage	  of	  this	  approach	  is	  that	  modules	  containing	  
different	  supporting	  or	  therapeutic	  cells	  can	  also	  be	  mixed	  together	  in	  a	  desirable	  ratio	  
to	  build	  more	  complex	  functional	  tissue	  structures.	  Another	  advantage	  of	  this	  approach	  
is	  that	  the	  modular	  design	  allows	  for	  uniform	  cell	  seeding	  (by	  controlling	  the	  cell	  density	  
within	  each	  of	  the	  individual	  modular	  building	  blocks),	  as	  well	  as	  controlled	  mixing	  of	  
different	  cell	  populations	  (by	  mixing	  together	  modules	  encapsulating	  different	  
functional	  cells,	  in	  different	  ratios),	  and	  is	  scalable	  (increasingly	  larger	  tissue	  constructs	  
can	  be	  made	  by	  assembling	  increasing	  numbers	  of	  modular	  building	  blocks.)	  The	  three-­‐
dimensional	  tissues	  assembled	  using	  this	  method	  have	  an	  intrinsic	  vasculature,	  are	  
scalable,	  have	  uniform	  cell	  density	  throughout	  the	  construct,	  and	  allow	  for	  the	  mixing	  of	  
different	  cell	  types	  within	  the	  modules	  or	  by	  using	  modules	  with	  different	  types	  of	  
embedded	  cells,	  thus	  avoiding	  common	  limitations	  of	  conventional	  scaffolds	  and	  
fabrication	  techniques.	  	  
	   The	  major	  challenge	  to	  advance	  this	  modular	  approach	  has	  been	  to	  improve	  or	  
develop	  new	  methods	  for	  assembling	  modules	  in	  a	  more	  precise	  and	  controlled	  manner.	  
The	  other	  challenge	  has	  been	  to	  improve	  the	  resolution	  of	  the	  assembled	  3D	  constructs	  
by	  making	  better	  reproducible	  modules	  of	  even	  smaller	  dimensions.	  The	  mechanical	  
properties	  of	  the	  modular	  scaffolds	  can	  be	  improved	  by	  more	  conventional	  methods	  like	  
introducing	  fibers	  or	  membranes	  to	  support	  the	  modular	  constructs.	  	  
	  
Nanofibers	  for	  Modular	  Tissue	  Engineering	  
Recent	  advances	  in	  nanotechnology	  and	  material	  science	  have	  made	  nanofiber	  
polymers	  an	  attractive	  choice	  among	  biomaterials	  for	  enhancing	  biological	  and	  
mechanical	  properties	  of	  modular	  tissue	  engineering	  strategies.	  Polymeric	  nanofibers	  
have	  proven	  to	  be	  excellent	  substrates	  for	  cell	  attachment	  and	  growth,	  and	  the	  
microstructure	  of	  polymeric	  nanofiber	  grafts	  can	  predictably	  modulate	  cell	  behaviors	  
such	  as	  morphology,	  differentiation,	  ECM	  deposition,	  and	  migration.	  This	  nanofibrous	  
ECM	  provides	  mechanical	  strength,	  storage	  locations	  for	  biomolecules,	  and	  also	  
provides	  a	  template	  for	  tissue	  formation	  in	  development,	  regeneration,	  and	  remodeling.	  
Other	  properties	  of	  nanofiber	  polymers	  make	  them	  well	  suited	  for	  more	  specific	  
applications;	  for	  example,	  nanofibers	  may	  offer	  more	  physiologic	  mechanical	  properties	  
for	  load	  bearing	  tissues,	  directional	  alignment	  to	  structures	  with	  aligned	  morphologies,	  
and	  nanofiber	  meshes	  with	  fine	  pores	  act	  as	  membranes	  that	  allow	  transport	  of	  
nutrients	  and	  waste.	  Despite	  the	  advantages,	  key	  scientific	  issues,	  such	  as	  the	  effects	  of	  
ECM	  composition	  and	  temporal-­‐spatial	  effects	  of	  ECM	  materials	  on	  stem	  cell	  
differentiation,	  still	  need	  further	  investigation.	  
Challenges	  in	  translating	  these	  technologies	  to	  the	  clinical	  arena	  include	  
optimizing	  substrate	  topographical	  cues	  to	  promote	  desired	  cell	  responses	  and	  the	  
ability	  to	  design	  scaffolds	  with	  architecture	  conducive	  to	  the	  formation	  of	  tissue-­‐like	  
structures	  in	  vitro	  and	  in	  vivo.	  Although	  nanotopography	  can	  affect	  cellular	  behavior	  
through	  known	  mechanisms	  such	  as	  regulation	  of	  cell	  shape	  and	  surface	  protein	  
absorption	  properties,	  it	  is	  also	  possible	  that	  there	  are	  unknown	  effects	  associated	  with	  
nanotopographys	  as	  well.	  Cells	  can	  react	  to	  objects	  as	  small	  as	  5nm	  and	  it	  is	  possible	  
that	  nanostructures,	  especially	  those	  with	  similar	  dimensions	  to	  natural	  ECM,	  can	  
negatively	  influence	  cell	  behavior	  resulting	  in	  undesired	  clinical	  outcomes.	  It	  has	  been	  
shown	  that	  cell	  behavior	  can	  be	  highly	  dependent	  on	  the	  substrate	  that	  they	  are	  
cultured	  on,	  and	  the	  understanding	  of	  cell-­‐substrate	  interactions	  with	  nanostructures	  
could	  provide	  valuable	  information	  that	  would	  allow	  for	  the	  design	  of	  more	  effective	  
scaffolds.	  	  
	  
sNAG	  as	  a	  novel	  nanofiber	  substrate	  for	  Vascular	  Engineering	  
	   The	  design	  and	  selection	  of	  a	  biomaterial	  is	  a	  critical	  step	  in	  the	  development	  of	  
scaffolds	  for	  tissue	  engineering.	  [35]	  Studies	  have	  shown	  that	  nanofiber	  polymers	  of	  
natural	  origin	  are	  among	  the	  most	  attractive	  options,	  mainly	  due	  to	  their	  similarities	  
with	  the	  ECM,	  chemical	  versatility	  as	  well	  as	  typically	  good	  biological	  performance.	  [35]	  
A	  recent	  development	  in	  the	  design	  of	  naturally	  derived	  polymers	  is	  the	  large-­‐scale	  
isolation	  and	  purification	  of	  poly-­‐N-­‐acetyl	  glucosamine	  or	  pGlcNAc	  from	  a	  marine	  
microalga	  by	  Vournakis	  et	  al.	  [36]	  	  These	  pure	  nanofiber	  preparations	  have	  been	  tested	  
for	  their	  biocompatibility	  and	  show	  no	  toxic,	  allergic	  or	  deleterious	  effects	  and	  are	  
therefore	  considered	  completely	  biocompatible.	  These	  features	  make	  them	  an	  ideal	  
candidate	  for	  enhancing	  modular	  tissue	  engineering	  approaches.	  	  
	   Previous	  studies	  have	  shown	  that	  pGlcNAc	  nanofiber-­‐derived	  membranes	  
promote	  accelerated	  wound	  healing	  in	  both	  wild	  type	  animals	  and	  in	  those	  with	  delayed	  
wound	  healing	  phenotypes.	  Increased	  wound	  repair	  mediated	  by	  nanofiber	  treatment	  is	  
characterized	  by	  increased	  hemostasis	  [37,	  38]	  ,	  re-­‐epithelialization,	  granulation	  tissue	  
formation	  and	  angiogenesis	  [39].	  Expression	  of	  markers	  of	  angiogenesis	  [40,	  41]	  (VEGF),	  
cell	  migration	  (uPAR)	  and	  ECM	  remodeling	  (MMP3,	  MMP9)	  were	  also	  up-­‐regulated	  in	  
sNAG	  treated	  wounds	  compared	  with	  controls.	  Mechanistic	  studies	  by	  our	  laboratory	  
using	  these	  nanofibers	  in	  vitro	  and	  in	  vivo,	  have	  shown	  that	  due	  to	  their	  unique	  three-­‐
dimensional	  structure,	  these	  fibers	  directly	  bind	  to	  and	  stimulate	  integrin	  mediated	  
outside-­‐in	  signal	  transduction	  that	  is,	  at	  least	  in	  part,	  dependent	  on	  Akt1	  activation	  in	  EC	  
and	  in	  fibroblasts.	  In	  EC,	  we	  have	  shown	  that	  nanofiber	  stimulation	  results	  in	  increased	  
metabolism	  [42]	  enhanced	  innate	  immune	  responses	  leading	  to	  antibacterial	  activity,	  
and	  to	  increased	  endothelial	  cell	  motility	  and	  angiogenesis	  [43].	  In	  addition	  to	  changes	  
in	  activation	  of	  transcription	  factors	  such	  as	  Ets1	  and	  PGC1a,	  nanofiber	  stimulation	  
results	  in	  marked	  increases	  in	  VEGF	  expression	  and	  interleukins	  such	  as	  IL-­‐1	  [40].	  	  
pGlcNAc	  nanofiber-­‐treated	  wounds	  were	  also	  shown	  to	  exhibit	  reduced	  scarring,	  
increased	  tensile	  strength	  and	  elastic	  modulus	  compared	  to	  untreated	  wounded	  skin	  
and	  this	  corresponds	  with	  higher	  collagen	  and	  elastin	  content	  as	  determined	  by	  
hydroxyproline	  analyses	  and	  immunohistological	  examination.	  We	  also	  observed	  
increased	  tropoelastin	  staining	  in	  sNAG	  treated	  cells.	  These	  findings	  suggest	  that	  sNAG	  
treatment	  results	  in	  increased	  tensile	  strength	  as	  well	  as	  increased	  elasticity	  and	  
supports	  the	  theory	  that	  nanofiber	  treatment	  decreases	  scarring	  while	  concurrently	  
increasing	  the	  mechanical	  properties	  of	  healing	  tissue.	  Importantly,	  these	  effects	  are	  
correlated	  with	  increased	  angiogenesis	  and	  vascular	  cell	  signaling.	  In	  control	  
experiments,	  compounds	  containing	  similar	  repetitive	  sugar	  moieties	  lacking	  sNAG	  
specific	  nanofiber	  structure	  (e.g.	  chitin/chitosan	  which	  have	  a	  B-­‐sheet-­‐type	  structure)	  do	  
not	  possess	  this	  biological	  activity	  [44,	  45].	  These	  findings	  suggest	  that	  pGlcNAc	  
nanofibers	  can	  be	  used	  to	  not	  only	  provide	  an	  optimal	  substrate	  for	  cell	  attachment	  and	  
growth,	  but	  also	  improve	  the	  mechanical	  integrity	  of	  modular	  tissue-­‐engineering	  
strategies;	  thus	  providing	  combinatorial	  advantages	  using	  a	  single	  biomaterial.	  	  
	  
	  
	   	  
CHAPTER	  2:	  THESIS	  OVERVIEW	  
	  
Goal:	  Augment	  tissue	  regeneration	  by	  rapid	  anastomosis	  of	  engineered	  autologous	  
microtissues	  with	  host	  vasculature.	  	  
	  
Objective:	  Develop	  biomaterial-­‐based	  strategies	  to	  build	  vascularized	  modular	  tissue	  
engineered	  constructs.	  	  
	  
Approach:	  Our	  approach	  involves	  the	  combination	  of	  adult	  stem	  cells	  (i.e.	  UCB-­‐EPCs,	  
ADSC-­‐VSMCs)	  with	  AoAFs,	  to	  be	  used	  for	  generation	  of	  pre-­‐vascularized	  microtissue	  
aggregates.	  Preliminary	  results	  show	  that	  this	  type	  of	  spheroid-­‐based	  approach	  elicits	  
increased	  synthesis	  and	  secretion	  of	  vascular	  ECM,	  including	  elastin,	  which	  is	  not	  
typically	  expressed	  in	  post-­‐natal	  VSMCs,	  thus	  highlighting	  the	  importance	  of	  heterotypic	  
interactions	  between	  ECs	  and	  VSMCs	  for	  increased	  mechanical	  strength	  and	  stiffness	  of	  
vascular	  structures.	  Herein	  we	  propose	  to	  build	  on	  this	  approach	  by	  using	  a	  new	  bio-­‐
degradable	  compound	  with	  pro-­‐angiogenic	  properties	  derived	  from	  a	  marine	  diatom,	  
i.e.	  shortened	  poly-­‐n-­‐acetyl-­‐glucosamine	  (sNAG)	  nanofibers,	  as	  a	  scaffold	  for	  optimizing	  
the	  assembly	  of	  vascular	  spheroids.	  While	  sNAG	  nanofibers	  are	  known	  to	  improve	  a)	  EC	  
mobilization,	  b)	  angiogenesis/vascular	  assembly,	  and	  c)	  elaboration	  of	  elastin	  and	  other	  
ECM	  components	  that	  provide	  strength	  and	  elasticity	  to	  the	  vessel	  wall	  in	  vivo	  and	  in	  
ECs	  in	  vitro,	  the	  use	  of	  sNAG	  nanofibers	  to	  improve	  modular	  tissue	  engineering	  
approaches	  has	  not	  been	  studied.	  
	  
Hypothesis:	  sNAG	  nanofibers	  can	  be	  utilized	  for	  optimizing	  vascular	  spheroid	  assembly	  
and	  therefore	  the	  functionality	  of	  bioengineered	  or	  ischemic	  tissues.	  	  
	  
Rational:	  Engraftment	  and	  survival	  of	  transplanted	  vascular	  cells	  in	  the	  
microenvironment	  of	  host	  tissues	  may	  be	  improved	  by	  combining	  such	  cells	  with	  
biodegradable	  matrices	  to	  delay	  apoptosis	  and	  enhance	  regenerative	  properties.	  
	  
Specific	  Aim-­‐1:	  Determine	  the	  effects	  of	  sNAG	  nanofibers	  on	  UCB-­‐EPC	  assembly	  and	  
function	  in-­‐vitro:	  Although	  EPCs	  have	  shown	  great	  potential	  as	  cell-­‐based	  therapies	  for	  
treatment	  of	  ischemic	  tissues,	  the	  development	  of	  advanced	  and	  novel	  biomaterials	  to	  
direct	  the	  differentiation	  and	  assembly	  of	  these	  cells	  has	  yet	  to	  be	  realized.	  A	  promising	  
strategy	  requires	  the	  modification	  of	  natural	  or	  synthetic	  surfaces	  to	  mimic	  endogenous	  
proteins	  of	  the	  ECM.	  Previous	  studies	  have	  demonstrated	  that	  ECs	  will	  adhere	  to	  pseudo	  
ECM	  structures	  which	  in	  turn	  induce	  intracellular	  signaling	  cascades	  that	  are	  able	  to	  
direct	  cell	  behavior.	  The	  associated	  signaling	  interactions	  have	  the	  potential	  to	  promote	  
survival	  of	  transplanted	  cells	  by	  induction	  of	  cell-­‐specific	  adhesion	  to	  the	  matrix	  and,	  
once	  attached,	  by	  controlling	  the	  proliferation,	  differentiation,	  and	  assembly	  of	  these	  
vascular	  cells.	  Therefore,	  the	  first	  aim	  will	  test	  sNAG	  stimulated	  UCB-­‐EPCs	  for	  their	  
ability	  to	  differentiate	  into	  functional	  ECs,	  and	  whether	  they	  assemble	  into	  a	  cohesive	  
endothelium	  and	  form	  cell-­‐cell	  junctions.	  The	  hypothesis	  for	  this	  aim	  is	  that	  sNAG	  
nanofiber	  topographies	  will	  provide	  an	  optimal	  or	  instructive	  interface	  for	  inducing	  UCB-­‐
EPC	  differentiation	  towards	  the	  EC	  lineage	  and	  will	  enhance	  the	  assembly	  of	  UCB-­‐EPCs	  
into	  a	  cohesive	  endothelium.	  	  
	  
Specific	  Aim-­‐2:	  Determine	  the	  effects	  of	  sNAG	  nanofibers	  on	  UCB-­‐EPC:ADSC-­‐
VSMC:AoAF	  co-­‐assembly	  and	  maturation	  of	  vascular	  networks	  in-­‐vitro:	  While	  delivery	  
of	  EPCs	  has	  been	  shown	  to	  be	  successful	  in	  promoting	  new	  capillary	  formation	  in	  vivo	  
and	  in	  vitro,	  the	  structure	  of	  the	  newly	  formed	  vessels	  is	  often	  non-­‐ideal.	  The	  vessels	  
can	  be	  immature,	  leaky,	  and	  lack	  essential	  cellular	  and	  extracellular	  components	  
required	  for	  proper	  function.	  Immature	  vascular	  structures	  may	  result	  in	  poor	  blood	  
perfusion	  and	  possibly	  vessel	  regression	  upon	  a	  decrease	  in	  the	  vascular	  stimulus.	  In	  
addition,	  the	  formation	  of	  small	  capillaries	  alone	  is	  not	  likely	  to	  be	  sufficient	  for	  
vascularization	  of	  large,	  complex	  tissues,	  which	  are	  often	  required	  for	  bioengineering	  
strategies.	  Thus,	  the	  second	  aim	  is	  focused	  not	  only	  on	  the	  initial	  assembly	  of	  vascular	  
networks,	  but	  on	  the	  expansion	  and	  stabilization	  of	  neovessels,	  which	  means	  the	  
formation	  of	  mature,	  long-­‐lasting	  structures.	  We	  will	  test	  whether	  sNAG	  nanofibers	  
induce	  physiologic	  alignment	  and	  organization	  of	  vascular	  cell	  types,	  whether	  sNAG	  
nanofibers	  facilitate	  recruitment	  of	  mural	  cells	  to	  nascent	  vascular	  structures,	  and	  
whether	  sNAG	  nanofibers	  augment	  vessel	  stabilization	  via	  synthesis	  and	  deposition	  of	  
basement	  membrane	  proteins.	  The	  hypothesis	  of	  this	  aim	  is	  that	  sNAG	  nanofibers	  will	  
enhance	  heterotypic	  interactions	  between	  vascular	  cell	  types	  which	  will	  result	  in	  the	  
formation	  of	  a	  mature	  and	  stabilized	  vascular	  network.	  	  	  
	  
CHAPTER	  3:	  METHODS	  AND	  MATERIALS	  
	  
1. Engineering	  of	  pGlcNAc	  (sNAG)	  Nanofiber	  Substrates:	  	  
Native	  diatom-­‐derived	  pGlcNAc	  (Marine	  Polymer	  Technologies,	  Inc.	  Danvers,	  
MA,	  USA)	  fibers	  have	  average	  length	  dimensions	  of	  ~	  80	  µm	  and	  a	  molecular	  weight	  of	  ~	  
3,000,000	  Da.	  Gamma	  radiation	  of	  NAG	  fibers	  resulted	  in	  length	  shortening,	  so	  that	  the	  
resultant	  biodegradable	  nanofibers	  (sNAG)	  have	  an	  average	  length	  of	  4	  µm	  to	  7	  µm,	  a	  
width	  of	  100	  nm	  to	  150	  nm,	  and	  a	  thickness	  of	  40	  nm	  to	  60	  nm,	  as	  previously	  measured	  
by	  electron	  microscopy.	  After	  this	  treatment,	  while	  the	  molecular	  weight	  decreases	  to	  
roughly	  60,000	  Da,	  the	  polymeric	  nanofibers	  maintain	  their	  unique	  3D	  structure.	  All	  
sNAG	  nanofibers	  are	  free	  of	  proteins,	  metal	  ions,	  and	  other	  contaminants.	  [41]	  An	  
aqueous	  master-­‐stock	  of	  10	  mg/ml	  sNAG	  nanofiber	  solution	  was	  kindly	  provided	  by	  the	  
Muise-­‐Helmericks	  lab.	  The	  two	  concentrations	  of	  polymer	  solutions	  studied	  for	  modular	  
scaffolds	  were	  a)	  10	  µg/ml	  and	  b)	  100	  µg/ml.	  	  
	  
2. Isolation,	  Characterization,	  and	  Culture	  of	  Cells:	  	  
	  
2.1	  UCB-­‐EPC	  Isolation	  and	  Characterization:	  (Studies	  performed	  previously	  in	  Dr.	  Fan	  
Lab)	  
EPCs	  were	  isolated	  and	  characterized	  in	  collaboration	  with	  Dr.	  Fan’s	  lab.	  Briefly,	  
unseparated	  cord	  blood	  will	  be	  diluted	  1:4	  with	  Hank’s	  Balanced	  Saline	  Solution	  (HBSS,	  
Gibco-­‐BRL,	  Grand	  Island,	  NY,	  USA).	  Cord	  blood	  mononuclear	  cells	  were	  then	  isolated	  
using	  Ficoll	  density	  gradient	  centrifugation	  (Lymphoprep).	  Recovered	  cells	  were	  washed	  
twice	  with	  HBSS	  and	  enumerated.	  They	  were	  then	  re-­‐suspended	  in	  phosphate	  buffered	  
saline	  (PBS).	  Uniform	  magnetic	  beads	  (Miletnyi	  Biotech,	  Bergish-­‐Gladbach,	  Germany)	  
coated	  with	  a	  monoclonal	  antibody	  specific	  for	  human	  CD34	  was	  then	  used	  to	  separate	  
out	  CD34+	  cells.	  These	  cells	  were	  then	  re-­‐suspended	  in	  300	  µl	  PBS,	  5	  mM	  EDTA.	  They	  
were	  then	  incubated	  with	  beads	  (ratio	  100	  µl	  beads	  per	  10^8	  cells)	  for	  15	  minutes	  at	  4C	  
and	  processed	  through	  a	  MACS	  separation	  column	  to	  obtain	  purified	  CD34+	  cells.	  	  
For	  identification	  of	  EPCs,	  the	  purified	  mononuclear	  cells	  were	  incubated	  with	  
FTIC-­‐labeled	  anti-­‐KDR	  (Sigma	  Chemical	  Co.	  St.	  Louis,	  MO,	  USA),	  anti-­‐AC133-­‐PE	  (Miltenyi	  
Biotech),	  anti-­‐CD31	  (Pharmigen,	  San	  Diego,	  CA,	  USA),	  and	  anti-­‐CD34	  (Becton-­‐Dicklinson,	  
San	  Jose,	  CA,	  USA)	  antibody.	  The	  percentage	  of	  positive	  cells	  were	  then	  analyzed	  by	  
two-­‐color	  flow	  cytometry	  (FACScan,	  Becton	  Dicklinson)	  and	  compared	  to	  an	  IgG	  isotype	  
control.	  	  
	  
All	  procedures	  for	  collecting	  human	  tissue	  (umbilical	  cord	  EPCs)	  were	  approved	  by	  the	  
Medical	  University	  of	  South	  Carolina	  Institutional	  Review	  Board.	  
	  
2.2	  Directed	  Differentiation	  of	  Human	  ADSCs	  to	  the	  VSMC-­‐lineage	  In-­‐vitro:	  (Studies	  
performed	  previously	  in	  Dr.	  Visconti	  Lab)	  	  
To	  investigate	  the	  SMC-­‐potential	  of	  ADSCs,	  we	  developed	  an	  ex	  vivo	  
differentiation	  protocol	  that	  directs	  the	  smooth	  muscle	  differentiation	  of	  hADSCs	  
without	  introduction	  of	  transgenes	  or	  exposure	  to	  reagents	  that	  non-­‐specifically	  alter	  
DNA	  (e.g.,	  5-­‐azacytadine).	  To	  accomplish	  this,	  we	  modified	  the	  protocol	  described	  by	  
Ross	  et	  al.	  [46]	  who	  differentiated	  MAPCs	  to	  the	  VSMC	  lineage:	  ADSCs	  (CD29+,	  CD44+,	  
CD73+,	  CD90+,	  CD105+,	  CD166+;	  CD14-­‐,	  CD31-­‐,	  CD45-­‐,	  Lin1-­‐;	  (Lonza)	  are	  plated	  at	  2.0	  x	  
10^5	  cells/cm^2	  on	  tissue	  culture	  plastic	  in	  serum-­‐free	  ADSC	  medium	  supplemented	  
with	  5.0	  ng/ml	  TGF-­‐b1	  (R&D	  Systems,	  Minneapolis,	  MN,	  USA)	  with	  medium	  changes	  
every	  2	  days.	  After	  6	  days	  in	  differentiation	  medium,	  cells	  are	  moved	  to	  expansion	  
medium	  (ADSC	  medium	  supplemented	  with	  5%	  fetal	  bovine	  serum	  (FBS)	  (Invitrogen,	  
Carlsbad,	  CA,	  USA),	  and	  5.0	  ng/ml	  TGF-­‐b1	  (R&D	  Systems,	  Minneapolis,	  MN,	  USA)	  Cells	  
were	  passaged	  every	  6	  days	  using	  using	  Trypsin/EDTA	  (0.025%	  Trypsin	  and	  0.01%	  EDTA)	  
(Cascade	  Biologics,	  Eugene,	  OR,	  USA)	  
	  
2.3	  In-­‐vitro	  Expansion	  of	  Cells:	  
Human	  microvascular	  endothelial	  cells	  -­‐	  cardiac	  (hMVECs-­‐C)	  and	  human	  aortic	  
adventitial	  fibroblasts	  (AoAFs)	  were	  purchased	  from	  Lonza.	  hADSCs	  were	  also	  purchased	  
commercially	  from	  Lonza.	  Cells	  were	  cultured	  in	  75cm^2	  culture	  flasks	  (VWR,	  
Bridgeport,	  NJ,	  USA)	  in	  37C,	  5%	  CO2	  humidified	  incubators.	  HMVECs-­‐C	  and	  UCB-­‐EPCs	  
were	  cultured	  in	  EGM-­‐2	  media	  (Lonza):	  Endothelial	  basal	  medium-­‐2	  supplemented	  with	  
EGM	  SingleQuots	  containing	  hydrocortisone,	  2%	  fetal	  bovine	  serum	  (FBS),	  human	  
fibroblast	  growth	  factor-­‐b	  (hFGF-­‐B),	  vascular	  endothelial	  growth	  factor	  (VEGF),	  insulin-­‐
like	  growth	  factor-­‐1	  (IGF-­‐1),	  ascorbic	  acid,	  heparin,	  human	  epidermal	  growth	  factor	  
(hEGF),	  and	  GA-­‐100	  (gentamicin,	  amphotericin-­‐B).	  ADSC-­‐VSMCs	  were	  cultured	  in	  
expansion	  medium	  as	  previously	  described	  (serum-­‐free	  ADSC-­‐medium,	  5%	  FBS,	  5.0%	  
TGF-­‐b1).	  AoAF	  were	  cultured	  in	  stromal	  cell	  basal	  media	  (SCGM),	  (Lonza)	  supplemented	  
with	  SingleQuot	  growth	  factors:	  (hFGF-­‐B,	  insulin,	  10%	  FBS,	  GA-­‐1000).	  AoAFs,	  hMVEC-­‐Cs,	  
and	  UCB-­‐EPCs	  were	  passaged	  (P3-­‐P8)	  using	  Trypsin/EDTA	  solution	  (Cascade	  Biologics)	  
and	  harvested	  when	  80%	  confluent.	  ADSC-­‐VSMCs	  were	  passaged	  (P3-­‐P6)	  using	  
Trypsin/EDTA	  solution	  (Cascade	  Biologics)	  and	  harvested	  at	  90%	  confluency.	  	  
	  
3. Biofabrication	  of	  Vascular	  Microtissue	  Spheroids	  
	  
3.1	  Casting	  of	  Micro-­‐molded	  Non-­‐adhesive	  Hydrogels:	  
Non-­‐adherent	  gels	  for	  gravity-­‐enforced	  spheroid	  assembly	  were	  casted	  using	  
Microtissues	  3D	  Petri	  Dish™	  24-­‐35	  Large	  Spheroids	  molds	  (MicroTissues	  Inc.,	  Sharon,	  
MA,	  USA).	  Briefly,	  a	  suspension	  of	  2%	  w/v	  agarose	  (Fisher	  Scientific.	  Waltham,	  MA,	  USA)	  
in	  sterile	  0.9%	  NaCl	  was	  prepared	  and	  subsequently	  heated	  in	  the	  microwave.	  Using	  
aseptic	  technique,	  330	  µl	  of	  molten	  hot	  agarose	  was	  pipetted	  into	  a	  24-­‐series	  micro-­‐
mold	  (35	  hemispheric	  circular	  recesses,	  400	  µm	  diameter	  800	  µm	  deep	  in	  a	  5	  x	  7	  array).	  
After	  the	  agarose	  was	  cooled,	  the	  molds	  were	  removed	  by	  gently	  flexing	  the	  rubber	  
platform.	  When	  the	  gelled	  agarose	  was	  removed	  from	  the	  micro-­‐mold,	  it	  was	  then	  
transferred	  to	  a	  standard	  24-­‐well	  tissue	  culture	  dish	  (Fischer	  Scientific).	  The	  wells	  were	  
filled	  with	  cell	  culture	  medium	  (EGM-­‐2	  for	  homotypic	  cell	  culture	  and	  serum-­‐free	  ADSC-­‐
medium	  supplemented	  with	  5.0%	  TGF-­‐b1	  for	  heterotypic	  cell	  culture)	  and	  incubated	  for	  
30	  min	  at	  37C	  for	  equilibration	  of	  the	  agarose	  gel.	  Culture	  medium	  was	  aspirated	  prior	  
to	  experimentation.	  	  
	  
3.2	  Assembly	  of	  Microtissue	  Spheroids	  in	  the	  Micro-­‐molded	  Recessions:	  
Microtissue	  spheroids	  were	  generated	  using	  Microtissues	  3D	  Petri	  Dish™24-­‐35	  
Large	  Spheroids	  (MicroTissues	  Inc.)	  molds	  according	  to	  established	  procedures.	  Cells	  
were	  trypsinzed,	  counted,	  and	  re-­‐suspended	  to	  the	  desired	  cell	  density	  (280,000	  
cells/75	  µl;	  approximately	  8,000	  cells/spheroid).	  Prior	  to	  seeding,	  homotypic	  (UCB-­‐EPCs	  
and	  hMVECs-­‐C	  only)	  cultures	  were	  re-­‐suspended	  in	  EGM-­‐2	  media	  and	  treated	  with	  VEGF	  
50	  ng/ml,	  sNAG	  10	  µg/ml,	  or	  sNAG	  100	  µg/ml.	  For	  heterotypic	  (UCB-­‐EPC:ADSC-­‐
VSMC:AoAF)	  cultures,	  cells	  were	  re-­‐suspended	  in	  serum-­‐free	  ADSC-­‐medium	  
supplemented	  with	  5.0	  nm/ml	  TGF-­‐b1	  and	  treated	  with	  VEGF	  50	  ng/ml,	  sNAG	  10	  µg/ml,	  
or	  sNAG	  100	  µg/ml.	  For	  heterotypic	  cell	  suspensions,	  ratios	  of	  cell	  types	  consisting	  of	  
3:1:2	  were	  used	  such	  that	  the	  total	  seeding	  density	  was	  held	  constant	  (e.g.	  280,000	  
cells/75	  µl;	  approximately	  8,000	  cells/spheroid).	  Cell	  suspensions	  were	  then	  added	  
dropwise	  via	  micropipette	  to	  the	  center	  of	  the	  rectangular	  recess	  seeding	  chamber	  of	  
each	  gel.	  Initial	  settling	  of	  cells	  was	  facilitated	  by	  manual	  agitation	  and	  swirling	  of	  
culture	  plates	  to	  ensure	  homogenous	  distribution	  into	  the	  hemispheric	  circular	  recesses.	  
Cells	  were	  allowed	  to	  settle	  for	  approximately	  10	  min	  before	  additional	  corresponding	  
medium	  was	  added	  to	  the	  cell	  culture	  plate	  by	  pipetting	  into	  the	  media	  exchange	  ports	  
(1.0	  ml/well	  for	  a	  24-­‐well	  plate).	  Cultures	  were	  fully	  immersed	  in	  their	  respective	  culture	  
media,	  which	  were	  maintained	  in	  a	  37C,	  5%	  CO2	  humidified	  incubator	  for	  24	  or	  72	  
hours.	  Media	  and	  supplemental	  factors	  were	  refreshed	  daily	  for	  the	  duration	  of	  culture.	  	  
	  
3.3	  Whole-­‐mount	  Fixation	  of	  Microtissue	  Spheroids:	  	  
Microtissues	  were	  washed	  three	  times	  in	  phosphate-­‐buffered	  saline	  (PBS;	  150	  
mM	  NaCl,	  6.5	  mM	  Na2HPO4-­‐2H2O,	  2.7	  mM	  KCL,	  1.5	  mM	  KH2PO4,	  pH	  7.4;	  (Sigma	  
Chemicals	  Co)	  and	  fixed	  for	  30	  min	  in	  4%	  paraformaldehyde	  (Sigma	  Chemicals).	  
Following	  fixation,	  microtissue	  spheroids	  were	  rinsed	  thoroughly	  in	  PBS	  supplemented	  
with	  sodium	  azide	  (PBSA;	  NaN3,	  0.01%	  v/v)	  before	  undergoing	  permeabilization	  with	  
phosphate-­‐buffered	  Trition	  X-­‐100	  (0.1%	  Trition	  X-­‐100/PBS	  +	  0.01%	  sodium	  azide).	  
Permeabilized	  microtissues	  were	  washed	  again	  in	  PBSA,	  followed	  by	  incubation	  in	  
Background	  Buster	  (Innovex	  Biosciences,	  Richmond,	  CA,	  USA)	  blocking	  solution	  for	  1h	  at	  
room	  temperature	  on	  an	  orbital	  shaker.	  Microtissue	  spheroids	  were	  washed	  another	  
three	  times	  in	  PBSA	  and	  prepared	  for	  immunolabeling.	  	  	  
	  
3.4	  Immunofluorescence	  Labeling	  of	  Microtissue	  Spheroids:	  
Primary	  antibodies	  specific	  for	  desired	  proteins	  as	  well	  as	  animal-­‐matched	  
fluorescence-­‐labeled	  secondary	  antibodies	  were	  diluted	  in	  3%	  BSA-­‐containing	  Tris-­‐
buffered	  saline	  (TBS,	  20	  mM	  Tris	  base,	  155	  mM	  NaCl,	  2	  mM	  EGTA,	  2	  mM	  MgCl2).	  
Immunofluorescence-­‐based	  analysis	  of	  homotypic	  (UCB-­‐EPCs	  and	  hMVECs-­‐C	  only)	  
microtissues	  required	  antibodies	  specific	  for	  mouse	  anti-­‐human	  PECAM-­‐1	  IgG1	  kappa	  
(Abnova,	  Taipei,	  Taiwan;	  diluted	  1:100).	  Alternatively,	  double	  and	  triple	  labeling	  of	  
heterotypic	  (UCB-­‐EPC:ADSC-­‐VSMC:AoAF)	  microtissues	  required	  antibodies	  specific	  for	  
mouse	  anti-­‐human	  PECAM-­‐1	  IgG1	  kappa	  (Abnova;	  diluted	  1:100),	  goat	  anti-­‐human	  
aSMA	  IgG	  (Abcam,	  Cambridge,	  MA,	  USA;	  diluted	  1:200),	  rabbit	  anti-­‐human	  HSP-­‐47	  IgG	  
(Abcam;	  diluted	  1:150),	  rabbit	  anti-­‐human	  collagen-­‐I	  IgG	  (Cedarlane,	  Burlington,	  NC,	  
USA;	  diluted	  1:200),	  and	  rabbit	  anti-­‐human	  collagen-­‐IV	  IgG	  (Cedarlane;	  diluted	  1:200).	  
Primary	  antibodies	  were	  visualized	  using	  animal-­‐matched	  secondary	  antibodies	  
including:	  Cy3-­‐coupled	  anti-­‐mouse	  (Sigma	  Aldrich;	  diluted	  7:1000),	  Cy5-­‐coupled	  anti-­‐
goat	  (Jackson	  ImmunoResearch;	  diluted	  7:1000),	  and	  FITC-­‐coupled	  anti-­‐rabbit	  secondary	  
antibodies	  (Sigma-­‐Aldrich;	  diluted	  7:1000).	  Primary	  and	  secondary	  antibodies	  were	  
sequentially	  incubated	  with	  microtissue	  spheroids	  for	  24	  hours	  at	  4C	  with	  three	  PBSA	  
washings	  in	  between.	  Counterstain	  with	  Hoechst	  33353	  for	  24	  hours	  at	  4C	  (Molecular	  
Probes,	  Eugene,	  OR,	  USA;	  diluted	  1:10,000)	  was	  used	  to	  visualize	  cell	  nuclei.	  After	  
rinsing	  at	  room	  temperature	  in	  PBSA,	  samples	  were	  mounted	  whole	  onto	  concave	  glass	  
slides	  (Fisher	  Scientific)	  to	  prevent	  destruction	  of	  the	  3D	  microtissue	  structure.	  
Coverslips	  were	  mounted	  onto	  microscope	  slides	  using	  Fluoro-­‐Gel	  (Electron	  Microscopy	  
Sciences,	  Hatfield,	  PA,	  USA)	  as	  a	  mounting	  medium	  and	  sealed	  using	  nail	  enamel.	  	  
	  
3.5	  Fluorescence-­‐based	  Characterization	  of	  Microtissue	  Spheroid	  Morphologies	  by	  
Confocal	  Microscopy:	  
After	  immunolabeling,	  the	  cellular	  organization	  of	  the	  microtissue	  spheroids	  was	  
visualized	  using	  a	  Leica	  TCS	  SP5	  AOBS	  multiphoton	  confocal	  microscope	  system	  (Leica	  
Microsystems,	  Inc.,	  Exton,	  PA,	  USA).	  Images	  were	  taken	  in	  sequential	  multichannel	  
mode	  using	  the	  same	  confocal	  microscope	  settings	  for	  objective,	  gain,	  and	  offset,	  all	  
optimized	  to	  prevent	  fluorescence	  signal	  cross-­‐over.	  Lasers	  including:	  Ar-­‐Ion	  gas	  laser	  
488	  nm	  (FITC),	  HeNe	  543	  nm	  (Cy-­‐3),	  and	  633nm	  (Cy-­‐5)	  were	  used	  to	  illuminate	  samples.	  
Short	  wavelength	  excitation	  was	  used	  for	  UV	  dyes,	  such	  as	  Hoechst	  33353.	  Using	  63x	  
and	  40x	  (total	  magnification	  630x	  and	  400x)	  oil	  immersion	  objectives,	  Z-­‐stack	  images	  
were	  generated	  by	  using	  the	  system-­‐optimized	  setting	  for	  scanning	  microtissue	  
sections.	  Digital	  images	  were	  obtained	  in	  TIF	  format	  and	  then	  processed	  for	  digital	  
segmentation.	  Individual	  images	  of	  a	  Z-­‐stack	  were	  then	  merged	  using	  ImageJ	  software	  
(NIH	  ImageJ,	  National	  Institute	  of	  Health,	  Bethesda,	  MD,	  USA),	  to	  generate	  3D	  
projections.	  Image	  stacks	  and	  subsets	  are	  presented	  as	  maximum	  projection	  images	  of	  
5-­‐stack	  2D	  composites.	  	  
The	  methods	  described	  above	  were	  used	  to	  qualitatively	  observe	  the	  presence	  of	  
newly	  formed	  vascular	  networks	  and	  to	  identify	  changes	  in	  ECM	  deposition	  and	  
organization	  as	  a	  result	  of	  interactions	  between	  vascular	  cell	  types.	  Identification	  of	  
these	  changes	  was	  visualized	  by	  focusing	  the	  microscopes	  field	  of	  view	  on	  either	  the	  
apex	  surface	  of	  the	  spheroid	  or	  at	  its	  cross-­‐section.	  Consistency	  in	  this	  approach	  was	  
maintained	  by	  predetermining	  the	  peak	  immunofluorescent	  intensity	  of	  the	  control	  
group,	  and	  then	  using	  those	  parameters	  as	  a	  baseline	  for	  comparison	  to	  the	  other	  
experimental	  groups.	  Between	  3	  and	  7	  replicates	  were	  performed	  for	  each	  experimental	  






4. In-­‐Vitro	  Tube	  Formation	  Assay	  
	  
4.2.1	  Matrigel	  Assay	  	  
Growth	  factor-­‐reduced	  and	  phenol	  red	  free	  Matrigel	  Basement	  Membrane	  
Matrix	  (BD	  Biosciences,	  San	  Diego,	  CA,	  USA)	  was	  used	  as	  a	  substrate	  for	  tube	  formation	  
assays	  to	  determine	  the	  functional	  ability	  of	  the	  isolated	  vascular	  cells	  to	  form	  networks.	  
In	  these	  studies,	  200	  µl	  of	  Matrigel	  (10mg/ml)	  was	  spread	  at	  the	  bottom	  of	  Lab-­‐Tek	  II	  
chamber	  slides	  (NUNC,	  Roskilda,	  Denmark)	  and	  used	  as	  a	  coat	  upon	  which	  cells	  were	  
seeded.	  Prior	  to	  seeding,	  UCB-­‐EPC	  cultures	  were	  re-­‐suspended	  (50,000	  cells/200	  µl	  per	  
well)	  in	  EGM-­‐2	  media	  and	  treated	  with	  VEGF	  50	  ng/ml,	  sNAG	  10	  µg/ml,	  or	  sNAG	  100	  
µg/ml.	  Experimentation	  with	  passage	  matched	  (P6)	  hMVECs-­‐C	  were	  used	  in	  parallel	  in	  
this	  assay	  under	  identical	  culture	  conditions.	  For	  heterotypic	  (UCB-­‐EPC:ADSC-­‐
VSMC:AoAF)	  cultures,	  cells	  were	  re-­‐suspended	  in	  serum-­‐free	  ADSC-­‐medium	  
supplemented	  with	  5.0	  ng/ml	  TGF-­‐b1	  and	  also	  treated	  with	  VEGF	  50	  ng/ml,	  sNAG	  10	  
µg/ml,	  or	  sNAG	  100	  µg/ml.	  The	  ratios	  of	  cell	  types	  consisting	  of	  3:1:2	  were	  used	  such	  
that	  the	  total	  seeding	  density	  was	  held	  constant	  (e.g.	  50,000/200	  µl	  per	  well).	  Cultures	  
were	  incubated	  in	  a	  humidified	  incubator	  at	  37C	  with	  5%	  CO2	  for	  7	  and	  24	  hours.	  	  
	  
4.2.2 Imaging	  and	  Analysis	  of	  Matrigel	  Assay	  	  
Following	  formation	  of	  vascular	  networks,	  cultures	  were	  fixed	  in	  4%	  
paraformaldehyde	  (Sigma	  Chemical	  Co)	  for	  30	  min	  and	  then	  washed	  multiple	  times	  with	  
PBSA.	  The	  initial	  assembly	  (7-­‐hour)	  or	  regression	  (24-­‐hour)	  of	  vascular	  networks	  was	  
visualized	  using	  a	  Leica	  DMIL	  inverted	  light	  microscope	  (Leica	  Microsystems).	  Phase-­‐
contrast	  images	  (20	  random	  fields/well)	  were	  acquired	  at	  20x	  (total	  magnification	  of	  
200x)	  to	  determine	  the	  number	  of	  sprouting	  and	  branching	  points	  of	  the	  newly	  formed	  
vascular	  networks.	  The	  average	  number	  of	  branches	  and	  sprouts	  per	  high-­‐powered	  field	  
were	  counted	  manually	  using	  imageJ	  software	  to	  form	  each	  n-­‐number	  from	  each	  well.	  
Results	  represent	  the	  mean	  branching	  and	  sprouting	  points	  from	  at	  least	  two	  different	  
experiments	  performed	  in	  duplicate.	  	  
	  
4.3.1 Modified	  Matrigel	  Assay	  
To	  visualize	  the	  ability	  of	  ADSC-­‐derived	  VSMCs	  to	  migrate	  toward	  and	  contribute	  
to	  the	  mural	  cell	  population	  around	  a	  nascent	  endothelial	  cell	  network,	  heterotypic	  cell	  
cultures	  were	  immunolabeled	  for	  proteins	  of	  interest.	  However,	  in	  order	  to	  produce	  gels	  
that	  were	  thin	  enough	  for	  successful	  confocal	  imaging,	  the	  standard	  protocol	  was	  
slightly	  modified.	  In	  brief,	  growth	  factor-­‐reduced	  Matrigel	  (100	  µl	  rather	  than	  200	  µl	  as	  
previously	  described)	  was	  thawed	  on	  ice	  overnight	  and	  spread	  evenly	  over	  each	  well	  of	  
Lab-­‐Tek	  II	  chamber	  slide	  (NUNC).	  Plates	  were	  incubated	  for	  30	  min	  at	  37C	  to	  allow	  for	  
polymerization	  of	  gels.	  Once	  solidified,	  serum-­‐free	  ADSC-­‐medium	  supplemented	  with	  
5.0	  ng/ml	  TGFb-­‐1	  was	  added	  for	  1	  hour	  at	  37C	  to	  equilibrate	  the	  matrices.	  
Approximately	  5.0x	  10^4	  UCB-­‐EPCs,	  ADSC-­‐derived	  VSMCs,	  and	  AoAFs	  (3:1:2	  ratio)	  were	  
plated	  in	  individual	  wells	  and	  incubated	  in	  a	  humid	  atmosphere	  at	  37C	  in	  5%	  CO2.	  After	  
7-­‐hours,	  cultures	  were	  fixed	  overnight	  in	  4C	  with	  2%	  (w/v)	  pipes-­‐buffered	  
paraformaldehyde	  (Sigma	  Chemical	  Co).	  	  
4.3.2	  Immunofluorescence	  Labeling	  of	  Tube-­‐like	  Networks	  	  
The	  cellular	  components	  of	  the	  vascular	  structures	  were	  characterized	  via	  
immunolabeling	  with	  mouse	  anti-­‐human	  PECAM-­‐1	  IgG1	  kappa	  (Abnova;	  diluted	  1:100)	  
as	  an	  endothelial	  cell	  marker,	  goat	  anti-­‐human	  aSMA	  IgG	  (Abcam;	  diluted	  1:200)	  as	  a	  
pericyte	  marker,	  and	  rabbit	  anti-­‐human	  HSP47	  IgG	  (Abcam;	  diluted	  1:150)	  as	  an	  ECM	  
marker.	  Primary	  antibodies	  were	  conjugated	  with	  coordinate	  secondary	  antibodies	  as	  
described	  previously;	  Cy3-­‐coupled	  anti-­‐mouse	  (Sigma	  Aldrich;	  diluted	  7:1000),	  Cy5-­‐
coupled	  anti-­‐goat	  (Jackson	  ImmunoResearch;	  diluted	  7:1000),	  and	  FITC-­‐coupled	  anti-­‐
rabbit	  secondary	  antibodies	  (Sigma-­‐Aldrich;	  diluted	  7:1000).	  Counterstain	  was	  achieved	  
using	  Hoechst	  33342	  (Molecular	  Probes:	  diluted	  1:10,000)	  to	  visualize	  cell	  nuclei.	  
Samples	  were	  washed	  three	  times	  and	  maintained	  in	  PBSA	  at	  4C	  until	  slides	  were	  ready	  
to	  be	  removed	  from	  the	  chamber.	  Coverslips	  were	  mounted	  onto	  slides	  using	  Fluoro-­‐Gel	  
(Electron	  Microscopy	  Sciences)	  as	  a	  mounting	  medium	  and	  sealed	  using	  nail	  enamel.	  
	  
4.3.3	  Fluorescence-­‐based	  Characterization	  of	  Tube-­‐like	  Network	  Formation	  by	  
Confocal	  Microscopy:	  	  	  
After	  immunolabeling,	  vascular	  network	  formation	  was	  visualized	  using	  a	  Leica	  
TCS	  SP5	  AOBS	  multiphoton	  confocal	  microscope	  system	  (Leica	  Microsystems).	  Images	  
were	  taken	  in	  sequential	  multichannel	  mode	  using	  the	  same	  confocal	  microscope	  
settings	  for	  objective,	  gain,	  and	  offset,	  all	  optimized	  to	  prevent	  fluorescence	  signal	  
cross-­‐over.	  Lasers	  including:	  Ar-­‐Ion	  gas	  laser	  488	  nm	  (FITC),	  HeNe	  543	  nm	  (Cy-­‐3),	  and	  
633nm	  (Cy-­‐5)	  were	  used	  to	  illuminate	  samples.	  Short	  wavelength	  excitation	  was	  used	  
for	  UV	  dyes,	  such	  as	  Hoechst	  33353.	  Using	  63x	  (total	  magnification	  630x)	  oil	  immersion	  
objective,	  Z-­‐stack	  images	  were	  generated	  by	  using	  the	  system-­‐optimized	  setting	  for	  
scanning	  matrigel	  sections.	  Digital	  images	  were	  obtained	  in	  TIF	  format	  and	  then	  
processed	  for	  digital	  segmentation.	  Individual	  images	  of	  a	  Z-­‐stack	  were	  then	  merged	  
using	  ImageJ	  software	  (NIH	  ImageJ)	  to	  generate	  3D	  projections.	  Image	  stacks	  and	  
subsets	  are	  presented	  as	  maximum	  projection	  images	  of	  5-­‐stack	  2D	  composites.	  	  
	  
5. Statistics:	  	  
Statistical	  analysis	  including	  calculations	  of	  standard	  error	  of	  means	  and	  mean	  
comparisons	  (Students	  t-­‐test)	  were	  performed	  using	  Prism	  (Version	  5.0,	  Graphpad	  
Software,	  La	  Jolla,	  CA)	  P-­‐values	  greater	  than	  0.05	  were	  determined	  to	  be	  statistically	  
significant.	  	  
	  
	   	  
CHAPTER	  4:	  RESULTS	  
1. Cell	  Culture	  and	  Spheroid	  Formation	  
Figure	  1:	  	  Human	  EPC	  Isolation,	  Culture,	  and	  Characterization	  (Studies	  performed	  
previously	  in	  Dr.	  Fan	  Lab).	  In	  previous	  studies	  performed	  by	  Dr.	  Fan,	  EPCs	  were	  isolated	  
from	  cord	  blood	  from	  healthy	  pregnant	  women.	  Blood	  was	  diluted	  with	  HBSS	  (hank’s	  
balanced	  salt	  solution)	  followed	  by	  ficoll	  density	  gradient	  centrifugation.	  Mononuclear	  
cells	  were	  collected	  and	  cultured	  in	  a	  collagen	  coated	  dish.	  Previous	  studies	  have	  shown	  
that	  culture	  in	  a	  collagen	  coated	  dish	  would	  result	  in	  late	  EPCs,	  which	  have	  function	  to	  
form	  tubes.	  After	  several	  days	  (7-­‐14	  days)	  of	  culture,	  the	  cells	  form	  colonies,	  suggesting	  
EPCs	  were	  cultured.	  Dr.	  Fan’s	  group	  then	  characterized	  the	  cultured	  EPCs	  using	  flow	  
cytometry	  analysis	  and	  show	  that	  cells	  are	  positive	  for	  CD34	  and	  VEGFR2.	  Fluorescence	  
microscopy	  analysis	  indicated	  that	  cells	  were	  positively	  stained	  by	  Dil-­‐acLDL	  and	  FITC-­‐
labeled	  lectin.	  When	  they	  cultured	  the	  cells	  in	  Matrigel	  matrix,	  they	  were	  able	  to	  form	  
tubes.	  All	  these	  characterizations	  suggest	  that	  they	  had	  successfully	  cultured	  human	  
EPCs.	  
	  
Figure	  2:	  Directed	  Differentiation	  of	  Human	  Adipose-­‐derived	  Stem	  Cells	  to	  the	  Vascular	  
Smooth	  Muscle	  Cell	  Lineage	  In	  vitro	  (Studies	  performed	  previously	  in	  Dr.	  Visconti	  Lab).	  
To	  examine	  VSMC	  characteristics	  of	  ADSC-­‐derived	  VSMCs,	  previous	  members	  of	  the	  
Visconti	  lab	  performed	  RT-­‐PCR	  and	  immunoblot	  analyses.	  ADSC-­‐derived	  VSMCs	  were	  
compared	  to	  ADSCs	  maintained	  in	  simple	  expansion	  medium	  (DMEM-­‐LG	  Invitrogen,	  
supplemented	  with	  Pen/Strep/glut	  and	  10%	  FBS).	  As	  seen	  in	  figure	  5:A.	  B	  both	  
transcript	  and	  protein	  for	  early	  markers	  of	  VSMC	  differentiation	  (aSMA	  and	  SM22)	  are	  
detected	  first	  and	  their	  levels	  of	  expression	  increase	  over	  time.	  Late	  VSMC	  markers	  
(Calponin	  and	  SM-­‐MHC)	  are	  detected	  later	  and	  in	  increasing	  amounts	  in	  differentiated	  
cell	  populations.	  Importantly,	  this	  temporo-­‐specific	  and	  increased	  expression	  of	  SMC	  
markers	  is	  similar	  to	  that	  exhibited	  by	  differentiating	  smooth	  muscle	  cells	  in	  vivo.	  To	  
further	  support	  their	  RT-­‐PCR	  and	  immunoblot	  analyses,	  they	  performed	  
immunofluorescent	  microscopy	  of	  these	  VSMC	  markers.	  As	  seen	  in	  Figure	  5:	  C,	  a	  limited	  
number	  of	  ADSCs	  express	  early	  VSMC	  differentiation	  markers	  (aSMA,	  SM22)	  and	  no	  
detectable	  late	  differentiation	  markers.	  As	  time	  in	  differentiation	  culture	  increases,	  
expression	  of	  early	  markers	  increases	  and	  late	  markers	  are	  detected	  and	  also	  increase	  
over	  time.	  	  
	  
Figure	  3:	  Microtissue	  Spheroid	  Fabrication	  and	  Processing.	  Microtissue	  spheroids	  were	  
generated	  using	  Microtissues	  3D	  Petri	  Dish™24-­‐35	  Large	  Spheroids	  (MicroTissues	  Inc.)	  
molds.	  Molds	  contained	  35	  hemispheric	  circular	  recesses	  with	  dimensions	  of	  400	  µm	  
diameters	  by	  800	  µm	  depths	  in	  a	  5	  x	  7	  array.	  Agarose	  was	  gelled	  around	  the	  micromold,	  
and	  on	  removal,	  the	  gel	  contained	  an	  array	  of	  recesses	  complementary	  to	  the	  mold	  
(Figure	  3:	  A-­‐D).	  A	  single	  cell	  suspension	  of	  early	  UCB-­‐EPCs,	  late	  UCB-­‐EPCs,	  and	  hMVECs-­‐
C	  were	  then	  seeded	  into	  the	  cell	  seeding	  chamber	  of	  the	  mold.	  The	  cells	  sank	  into	  the	  
recesses	  within	  1	  hour	  and	  formed	  a	  single	  spheroid	  (8,000	  cells/spheroid)	  of	  uniform	  
size	  in	  the	  bottom	  of	  each	  recess	  within	  24	  hours.	  Bright	  field	  microscopy	  revealed	  the	  
successfully	  fabricated	  300um	  diameter	  microtissues.	  (Figure	  3:	  E)	  
Figure	  4:	  EC	  Subculture	  and	  Comparison	  of	  Early-­‐outgrowth	  UCB-­‐EPCs,	  Late-­‐outgrowth	  
UCB-­‐EPCs,	  and	  hMVEC-­‐Cs.	  Early	  UCB-­‐EPCs,	  late	  UCB-­‐EPCs,	  and	  adult	  hMVECs-­‐C	  are	  
commonly	  studied	  in	  vascular	  engineering	  and	  regenerative	  medicine	  applications.	  
Thus,	  understanding	  inherent	  differences	  between	  these	  cell	  types	  can	  yield	  important	  
advancements	  in	  vascular	  regenerative	  medicine.	  To	  evaluate	  these	  differences,	  we	  
examined	  general	  EC	  surface	  marker	  expression	  of	  cell	  adhesion	  molecule	  hPECAM-­‐1.	  
Using	  immunofluorescence	  analysis,	  we	  found	  that	  early	  UCB-­‐EPCs	  had	  minimal	  
expression	  of	  the	  endothelial	  cell-­‐specific	  marker	  hPECAM-­‐1.	  In	  contrast,	  late	  UCB-­‐EPCs	  
and	  hMVEC-­‐Cs	  show	  profuse	  expression	  with	  a	  comparable	  distribution	  pattern	  of	  
hPECAM-­‐1	  cell	  labeling.	  This	  result	  confirms	  that	  late	  UCB-­‐EPCs	  phenotype	  was	  similar	  
to	  that	  of	  mature	  hMVEC-­‐Cs	  when	  sub-­‐cultured	  in	  microtissue	  spheroids.	  
	  
	   	  
	  





















Figure	  1:	  Human	  umbilical	  cord	  blood	  derived	  endothelial	  progenitor	  cell	  isolation,	  
culture,	  and	  characterization	  (Studies	  performed	  previously	  in	  Dr.	  Fan’s	  lab).	  (a)	  Cord	  
blood	  mononuclear	  cells	  were	  isolated	  using	  Ficoll	  density	  gradient	  centrifugation.	  (b)	  
Uniform	  magnetic	  beads	  coated	  with	  monocloncal	  antibody	  specific	  for	  human	  CD34	  
was	  used	  to	  separate	  out	  CD34+	  cells	  and	  processed	  through	  a	  MACS	  separation	  
column.	  (c)	  Cells	  were	  identified	  using	  FITC-­‐labeled	  anti-­‐KDR,	  anti-­‐AC133-­‐PE,	  anti	  CD31,	  
and	  anti-­‐CD34	  antibodies	  and	  analyzed	  using	  two-­‐color	  flow	  cytometry.	  (d)	  Functional	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Figure	  2:	  Directed	  differentiation	  of	  human	  ADSCs	  to	  the	  VSMC-­‐lineage	  in	  vitro	  
(Studies	  performed	  previously	  in	  Dr.	  Visconti	  lab).	  (a)	  RT-­‐PCR	  analysis	  of	  smooth	  muscle	  
differentiation	  in	  differentiated	  ADSCs	  at	  0,	  4	  and	  8	  days	  in	  differentiation	  medium.	  (b)	  
Immunoblot	  analysis	  of	  protein	  extracts	  of	  ADSC	  derived	  cells	  at	  0,	  4	  and	  8	  days	  in	  diff.	  
medium.	  αSMA	  =	  a-­‐smooth	  muscle	  actin,	  SM-­‐MHC	  =	  smooth	  muscle	  myosin	  heavy	  
chain;	  GAPDH	  =	  glyceraldehyde	  3-­‐phosphate	  dehydrogenase.	  
	  
Figure	  3:	  Directed	  differentiation	  of	  human	  ADSCs	  to	  the	  VSMC-­‐lineage	  in	  vitro	  
continued	  (Studies	  performed	  previously	  in	  Dr.	  Visconti	  lab).	  Immunofluorescence	  
analysis	  of	  ADSC	  derived	  SMCs	  at	  0,	  4	  and	  8	  days	  in	  diff.	  medium.	  Limited	  αSMA-­‐	  and	  
SM-­‐22-­‐	  positive	  cells	  were	  detected	  early	  upon	  addition	  of	  differentiation	  medium	  while	  
no	  cells	  were	  immunopositive	  for	  the	  later	  markers	  of	  SMC	  differentiation	  (calponin	  and	  
SM-­‐MHC).	  By	  4	  days	  in	  diff.	  medium,	  αSMA-­‐	  and	  SM-­‐22-­‐positive	  cells	  were	  detected	  at	  
markedly	  higher	  levels	  and	  calponin-­‐	  and	  SM-­‐MHCpositive	  cells	  were	  detected.	  By	  8	  days	  
in	  diff.	  medium,	  the	  majority	  of	  cells	  positive	  for	  αSMA	  and	  SM-­‐22	  and	  calponin-­‐	  and	  










Figure	  4:	  Fabrication	  of	  microtissue	  spheroids	  and	  sub-­‐culture	  optimization:	  (a-­‐d)	  
Fabrication	  of	  microtissue	  molds	  for	  vascular	  spheroid	  formation.	  (e)	  Assembling	  of	  
microtissues	  (EPCs)	  within	  the	  agarose	  of	  3D	  micro-­‐Petri	  dish	  (273,000	  cells/dish)	  (4x).	  (f-­‐
h)	  A	  representative	  image	  (20x)	  of	  early-­‐EPC,	  late-­‐EPC,	  and	  hMVEC-­‐C	  containing	  8,000	  
cells/spheroid.	  (blue	  Hoescht,	  red	  hPECAM1).	  
	  
	   	  





2. Specific	  Aim-­‐1:	  Determine	  the	  effects	  of	  sNAG	  nanofibers	  on	  UCB-­‐EPC	  assembly	  
and	  function	  in	  vitro.	  	  
	  
Figure	  5:	  sNAG	  Nanofibers	  Induce	  UCB-­‐EPC	  and	  hMVEC-­‐C	  Assembly	  and	  Cell-­‐Cell	  
Junction	  Formation.	  Previous	  studies	  have	  demonstrated	  that	  cell	  adhesion	  molecule	  
PECAM-­‐1	  expressed	  by	  ECs	  is	  crucial	  for	  vessel	  formation	  and	  maintenance.	  Therefore,	  
the	  effect	  of	  sNAG	  nanofibers	  on	  UCB-­‐EPC	  and	  hMVEC-­‐C	  monoculture	  spheroids	  was	  
investigated	  by	  confocal	  microscopy.	  Treatment	  with	  sNAG	  10ug/ml	  (Figure:	  A,	  B)	  
elicited	  profound	  effects	  on	  the	  organization	  and	  alignment	  of	  ECs.	  Our	  results	  further	  
show	  that	  hPECAM-­‐1	  positive	  cells	  (red)	  aligned	  circumferentially	  around	  the	  perimeter	  
of	  the	  spheroid,	  as	  well	  as	  along	  an	  inner	  core,	  in	  our	  sNAG	  10ug/ml	  treated	  cultures.	  
Spheroids	  treated	  with	  sNAG	  100ug/ml	  demonstrated	  preferential	  hPECAM-­‐1	  
localization	  to	  the	  periphery	  of	  the	  spheroid	  as	  well	  as	  increased	  expression	  around	  
what	  appears	  to	  be	  anastomosing	  ECs	  (white	  arrows).	  Analysis	  of	  immunofluorescent	  
images	  acquired	  from	  (control)	  50	  ng/ml	  VEGF-­‐treated	  spheroids	  show	  that	  ECs	  
circumscribed	  a	  single	  large	  central	  area	  that	  did	  not	  display	  immunoreactivity	  of	  
hPECAM1	  (Figure:	  A,	  B)	  
	  
Figure	  6:	  sNAG	  Nanofibers	  Effect	  UCB-­‐EPC	  Migration	  and	  EC	  Differentiation.	  To	  
determine	  whether	  sNAG	  nanofiber	  matrices	  induce	  EC	  migration	  within	  our	  spheroid	  
system,	  cross-­‐sections	  of	  spheroids	  were	  analyzed.	  The	  expression	  of	  surface	  adhesion	  
protein	  characteristically	  expressed	  by	  endothelial	  cells	  was	  evaluated	  by	  
immofluorescence	  microscopy	  (hPECAM-­‐1;	  red).	  Cross-­‐sections	  of	  monoculture	  
spheroids	  show	  localization	  of	  hPECAM-­‐1	  to	  the	  outer	  perimeter	  of	  the	  spheroids	  
(Figure	  7:	  A,	  B).	  In	  sNAG	  100	  ug/ml	  and	  control	  spheroids,	  immunofluorescence	  analysis	  
revealed	  a	  dense	  expression	  pattern	  at	  the	  periphery	  of	  the	  microtissues,	  a	  pattern	  that	  
was	  not	  observed	  in	  the	  50ng/ml	  VEGF	  or	  10ug/ml	  sNAG	  spheroids.	  In	  50	  ng/ml	  and	  
10ug/ml	  spheroids,	  hPECAM-­‐1	  was	  expressed	  more	  evenly	  and	  clearly	  resembling	  a	  
singular	  lumenized	  periphery	  with	  well-­‐established	  cell-­‐cell	  junctions.	  (Figure	  7:	  A,	  B).	  	  
Results	  of	  this	  study	  show	  that	  sNAG	  10ug/ml	  treated	  spheroids	  provide	  an	  optimal	  
substrate	  for	  EC	  migration	  (a	  key	  step	  in	  EC	  morphogenesis	  and	  tube	  remodeling)	  using	  
a	  less	  concentration	  of	  sNAG	  nanofibers.	  
	  
Figure	  7:	  Effect	  of	  sNAG	  Nanofibers	  on	  EC	  Function	  on	  2D	  Substrates	  
Late	  outgrowth	  EPCs	  spontaneously	  formed	  capillaries	  when	  plated	  on	  three-­‐
dimensional	  Matrigel	  extracellular	  matrix.	  At	  7hr,	  tube	  structures	  began	  to	  form	  (fig.	  
5a).	  After	  24	  hours,	  the	  cells	  coalesced	  and	  formed	  more	  discrete	  tubes	  (fig	  5b).	  Vessel	  
sprouting	  was	  significantly	  higher	  in	  sNAG	  10ug/ml	  treated	  spheroids	  and	  vessel	  
branching	  in	  100ug/ml	  sNAG	  treated	  spheroids.	  However,	  there	  were	  no	  significant	  
differences	  between	  other	  treatment	  groups	  were	  observed,	  indicating	  that	  kinetics	  of	  
the	  vasculogenesis	  properties	  of	  the	  cell	  types	  in	  Matrigel	  are	  effected	  by	  sNAG	  













Figure	  5:	  sNAG	  nanofibers	  effect	  UCB-­‐EPC	  and	  hMVEC-­‐C	  vascular	  assembly	  in	  vitro.	  
Representative	  immunofluorescent	  images	  of	  whole-­‐mount	  monoculture	  spheroids	  
labeled	  with	  antibodies	  directed	  against	  anti	  hPECAM-­‐1	  (red),	  and	  counter	  stained	  with	  
Hoescht	  nuclear	  stain	  (blue).	  Control	  spheroids	  	  (a	  and	  e)	  or	  spheroids	  treated	  with	  
50ng/ml	  of	  VEGF	  (b	  and	  f),	  demonstrate	  morphologies	  with	  minimal	  structural	  
alignment.	  Spheroids	  treated	  with	  10ug/ml	  sNAG	  (c	  and	  g)	  show	  increased	  hPECAM-­‐1	  
expression	  localized	  to	  the	  periphery	  of	  the	  spheroid	  (blue	  arrow).	  Spheroids	  treated	  
with	  100	  ug/ml	  sNAG	  (d	  and	  h)	  have	  increased	  peripheral	  hPECAM-­‐1	  expression	  as	  well	  
as	  anastomosing	  EC	  structures	  (white	  arrows).	  	  
	  




































Figure	  6:	  sNAG	  nanofiber	  matrices	  induce	  EC	  migration	  in	  microtissue	  spheroids.	  
Representative	  immunofluorescent	  images	  of	  cross-­‐sectioned	  monoculture	  spheroids	  
labeled	  with	  antibodies	  directed	  against	  anti	  hPECAM-­‐1	  (red),	  and	  counter	  stained	  with	  
Hoescht	  nuclear	  stain	  (blue).	  (a-­‐h)	  Epithelialization	  of	  EC	  cells	  in	  spheroid	  culture	  at	  1	  
day.	  	  (b,f	  and	  c,g)	  A	  section	  of	  a	  spheroid	  shows	  a	  peripheral	  monolayer	  of	  EC	  cells	  in	  
sNAG	  10ug/ml	  and	  VEGF	  50ng/ml	  and	  a	  core	  of	  nuclei	  labeled	  cells.	  (a,e	  and	  d,h)	  
Immunofluorescence	  dense	  hPECAM1	  strands	  indicative	  of	  tight	  junctional	  cell-­‐cell	  
contacts	  in	  control	  and	  sNAG	  100ug/ml	  spheroids.	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Figure	  7:	  2D	  Matrigel	  tube	  formation	  assay.	  Representative	  image	  of	  late-­‐outgrowth	  
EPCs	  treated	  with	  sNAG	  nanofibers	  or	  other	  known	  initiators	  of	  vascular	  assembly	  (VEGF	  
50ng/ml).	  sNAG	  10ug/ml	  demonstrated	  a	  significant	  increase	  in	  vessel	  sprouting	  
compared	  to	  VEGF	  50ng/ml	  and	  control.	  sNAG	  100ug/ml	  showed	  a	  strong	  trend	  in	  
vessel	  branch	  points,	  although	  was	  not	  statistically	  significant	  compared	  to	  VEGF	  
50ng/ml.	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SPECIFIC	  AIM-­‐2:	  Determine	  the	  effects	  of	  sNAG	  nanofibers	  on	  UCB-­‐EPC:ADSC-­‐
VSMC:AoAF	  co-­‐assembly	  and	  maturation	  of	  vascular	  networks	  in	  vitro.	  	  
	  
Figure	  8:	  sNAG	  Nanofibers	  Induce	  Lumen	  Formation	  and	  Vascular-­‐like	  Network	  
Assembly.	  Cell	  adhesion	  molecule	  PECAM-­‐1	  expression	  at	  the	  cell-­‐cell	  interface	  could	  be	  
used	  to	  indicate	  vascularlike	  structures	  or	  lumina.	  We	  sought	  to	  determine	  the	  
morphogenesis	  dynamics	  of	  UCB-­‐EPCs	  treated	  with	  sNAG	  10ug/ml,	  sNAG	  100ug/ml	  or	  
VEGF	  50ng/ml	  in	  heterotypic	  cell	  cultures.	  Immunofluorescence	  analysis	  for	  human	  
PECAM-­‐1	  detected	  EC	  lined	  vascular	  lumens	  in	  100	  ug/ml	  sNAG	  treated	  spheroids	  within	  
24	  hours	  of	  cell	  culture	  (Figure	  7a).	  This	  process	  continued	  with	  lumens	  increasing	  in	  
number	  and	  size,	  followed	  by	  their	  coalescence	  into	  larger	  structures	  (inset).	  By	  day	  3,	  
vascularlike	  networks	  grew;	  and	  we	  could	  clearly	  observe	  complex	  and	  comprehensive	  
structures	  within	  50	  ng/ml	  VEGF,	  10	  ug/ml	  sNAG,	  but	  most	  predominantly	  in	  100	  ug/ml	  
sNAG	  treated	  spheroids.	  Complex	  vascular	  networks	  with	  lumenized	  structures	  were	  
easily	  detected	  throughout	  the	  sNAG	  100ug/ml	  treated	  spheroids,	  suggesting	  a	  mature	  
vascular	  network	  (Figure	  7B).	  Results	  of	  this	  study	  indicate	  that	  lumen	  formation	  and	  
vascular	  network	  assembly	  is	  increased	  in	  the	  sNAG	  100ug/ml	  microtissue	  spheroids	  
	  
Figure	  9:	  Collagen	  Type-­‐1	  is	  Significantly	  Degraded	  by	  Day-­‐3	  sNAG	  Treated	  Microtissue	  
Spheroids.	  To	  determine	  the	  contribution	  of	  structural	  ECM	  proteins,	  we	  investigated	  
collagen	  type	  1	  deposition	  in	  sNAG	  treated	  spheroids.	  Significant	  contrast	  was	  shown	  
with	  the	  expression	  of	  type	  1	  collagen	  between	  24h	  and	  72h	  cultures	  treated	  with	  or	  
without	  sNAG.	  However,	  reduction	  in	  type	  1	  collagen	  expression	  was	  observed	  across	  all	  
experimental	  groups	  (Figure	  8A,	  B).	  Results	  of	  this	  study	  show	  that	  sNAG	  treated	  
microtissue	  spheroids	  undergo	  rapid	  ECM	  degradation	  by	  day	  3	  of	  cell	  culture.	  	  
	  
Figure	  10:	  Induction	  of	  VSMC	  Expression	  Markers	  by	  Day-­‐3	  in	  sNAG	  Treated	  
Microtissue	  Spheroids.	  Given	  the	  tempero-­‐specific	  degradation	  of	  Collagen	  type	  1	  by	  
sNAG	  treated	  spheroids,	  we	  wanted	  to	  determine	  whether	  sNAG	  nanofibers	  were	  
having	  an	  effect	  on	  the	  maintenance	  of	  VSMC	  phenotype	  in	  our	  ADSC-­‐VSMC	  cultures.	  
Time-­‐course	  experiments	  revealed	  a	  time-­‐dependent	  increase	  in	  aSMA	  expression	  in	  
sNAG	  10ug/ml	  and	  sNAG	  100ug/ml	  treated	  cultures	  (Figure	  9).	  The	  inductive	  effect	  of	  
sNAG	  nanofibers	  on	  aSMA	  expression	  could	  not	  be	  seen	  in	  day-­‐1	  cultures	  (data	  not	  
shown).	  In	  contrast,	  50ng/ml	  VEGF	  and	  control	  spheroids	  displayed	  diffuse	  aSMA	  
expression	  (Figure	  9).	  Notably,	  the	  expression	  of	  aSMA	  was	  located	  beneath	  hPECAM-­‐1	  
staining,	  indicating	  the	  formation	  of	  a	  multi-­‐layered	  cellular	  alignment	  (white	  arrows).	  	  
	  
Figure	  11:	  Coincident	  Heterotypic	  Cell	  Alignment	  and	  Collagen	  Type-­‐4	  Deposition	  in	  
sNAG	  Treated	  Microtissue	  Spheroids.	  To	  investigate	  the	  functional	  characteristics	  of	  the	  
ADSC-­‐VSMC	  phenotype	  by	  sNAG	  nanofibers,	  triple	  immunofluorescence	  (aSMA,	  
Collagen	  type	  4,	  and	  hPECAM1)	  using	  confocal	  microscopy	  was	  employed.	  We	  sought	  to	  
interrogate	  the	  ECM	  produced	  by	  EC-­‐VSMCs	  by	  examining	  the	  spatial	  relationship	  
between	  collagen	  IV,	  hPECAM-­‐1,	  and	  aSMA,	  in	  cross	  sections	  of	  microtissue	  spheroids.	  
3-­‐day	  cultures	  were	  examined	  for	  alignment	  of	  vascular	  cell	  types	  with	  associated	  
deposition	  of	  collagen	  type	  IV	  proteins.	  Three-­‐dimensional	  projections	  from	  confocal	  
microscopy	  revealed	  that	  collagen	  IV	  deposited	  in	  sNAG	  100ug/ml	  and	  10ug/ml	  treated	  
spheroids,	  but	  not	  in	  50ng/ml	  VEGF	  or	  control	  microtissue	  spheroids.	  These	  results	  
strongly	  suggest	  that	  sNAG	  nanofiber	  treated	  spheroids	  were	  organized	  into	  distinct	  
vascular	  layers	  with	  functional	  properties	  evidenced	  by	  physiologic	  deposition	  of	  
collagen	  type	  4.	  
	  
Figure	  12:	  sNAG	  Nanofibers	  Facilitate	  Pericyte	  Recruitment	  to	  the	  Ablumenal	  Surface	  
of	  EC-­‐Lined	  Tubes	  within	  Vascular	  Guidance	  Tunnels.	  Next,	  we	  wanted	  to	  determine	  
whether	  sNAG	  nanofibers	  enhanced	  the	  stabilization	  of	  vascular	  networks	  by	  enhancing	  
recruitment	  of	  ADSC-­‐VSMCs	  to	  the	  ablumenal	  surface	  of	  vascular	  networks.	  To	  do	  this,	  
we	  first	  verified	  the	  EC-­‐pericyte	  association	  of	  the	  vascular	  network	  generated	  by	  UCB-­‐
EPCs	  within	  our	  sNAG	  treated	  microtissue	  spheroids.	  Cross-­‐sections	  of	  sNAG	  100ug/ml	  
treated	  microtissues	  show	  whole	  vascularlike	  networks	  covered	  by	  aSMA	  +	  pericytes	  
(white	  arrows),	  especially	  on	  the	  abluminal	  endothelial	  surface,	  which	  could	  be	  
confirmed	  through	  3D	  images	  obtained	  by	  confocal	  microscopy	  (Figure	  10:	  white	  
arrows).	  Further	  analysis	  shows	  that	  matrix	  spaces	  (i.e.,	  vascular	  guidance	  tunnels)	  are	  
readily	  observed	  during	  morphogenesis	  that	  directly	  corresponds	  to	  the	  area	  
surrounding	  aSMA	  +	  cells	  (Figure	  10:	  sNAG	  100ug/ml,	  blue	  arrows).	  These	  data	  show	  
that	  a	  strong	  synergistic	  relationship	  exists	  between	  these	  2	  cell	  types	  during	  critical	  
extracellular	  remodeling	  events	  necessary	  for	  vasculogenic	  plexus	  assembly.	  	  
Basement	  membrane	  assembly	  on	  the	  abluminal	  surface	  of	  blood	  vessels	  is	  
required	  to	  initiate	  the	  interaction	  between	  ECs	  and	  pericytes	  as	  a	  critical	  step	  of	  vessel	  
maturation	  in	  vitro	  and	  in	  vivo.	  Thus,	  we	  explored	  the	  effect	  of	  sNAG	  treated	  
heterotypic	  cell	  cultures	  on	  basement	  membrane	  assembly	  around	  nascent	  blood	  vessel	  
networks.	  To	  determine	  the	  position	  of	  basement	  membrane	  matrix	  in	  relation	  to	  ECs,	  
pericytes,	  and	  vascular	  guidance	  tunnels	  (Figure	  10),	  we	  stained	  for	  collagen	  type	  4,	  
which	  shows	  its	  presence	  between	  the	  EC	  and	  pericyte	  surfaces	  surround	  the	  vascular	  
guidance	  tunnels	  (White	  arrows).	  Thus,	  under	  the	  100ug/ml	  sNAG	  treated	  spheroid	  
conditions,	  ECs	  and	  pericytes	  will	  co-­‐assemble	  into	  tube	  structures	  with	  an	  associated	  
basement	  membrane	  matrix	  (Figure	  10).	  Overall,	  our	  data	  strongly	  support	  the	  concept	  
that	  pericyte	  recruitment	  to	  EC-­‐lined	  tubes	  catalyzes	  extracellular	  deposition	  of	  
basement	  membrane	  matrix	  components	  using	  confocal	  microscopy.	  	  
	  

















Figure	  8:	  sNAG	  nanofibers	  induce	  lumen	  formation	  and	  vascular	  network	  assembly	  
over	  time.	  Representative	  immunofluorescent	  images	  of	  whole-­‐mount	  heterotypic	  
spheroids	  ((top	  row	  24h)	  and	  (bottom	  row	  72	  hours))	  labeled	  with	  antibodies	  directed	  
against	  anti	  hPECAM-­‐1	  (red).	  (Top	  row)	  sNAG	  100ug/ml	  spheroids	  form	  multiple,	  large	  	  
lumenized	  structures	  (white	  arrows)	  after	  24	  hrs	  in	  culture.	  In	  contrast,	  VEGF	  50ng/ml	  
and	  10ug/ml	  sNAG	  show	  moderate	  lumen	  formation	  (blue	  arrow),	  while	  control	  
spheroids	  were	  unable	  to	  form	  lumenized	  structures.	  (Bottom	  row)	  hPECAM-­‐1	  labeled	  
cells	  show	  the	  organization	  of	  UCB-­‐EPCs	  into	  a	  vascular-­‐like	  network	  after	  3	  days	  cell	  
culture	  (20x).	  sNAG	  100ug/ml	  treated	  spheroids	  assembled	  into	  complex	  vascular	  
networks	  with	  an	  organized,	  hierarchical	  organization	  (white	  arrow	  indicates	  branched	  
and	  elongated	  vascular	  networks).	  Spheroids	  treated	  with	  VEGF	  50ng/ml	  and	  10ug/ml	  
were	  also	  able	  to	  assemble	  into	  vascular	  networks	  by	  day	  3	  (white	  arrows).	  In	  contrast,	  
control	  spheroids	  maintained	  a	  quiescent	  EC	  phenotype	  and	  did	  not	  undergo	  


































Figure	  9:	  Collagen	  type	  1	  is	  reduced	  in	  sNAG	  treated	  spheroids	  after	  3	  days	  cell	  culture.	  
sNAG	  nanofiber	  treated	  spheroids	  significantly	  reduce	  Collagen	  type-­‐1	  deposition	  after	  
3-­‐days	  cell	  culture.	  Representative	  images	  of	  whole-­‐mount	  heterotypic	  spheroids	  (24	  
and	  72	  hours)	  labeled	  with	  antibodies	  directed	  against	  anti-­‐hPECAM1,	  anti-­‐human	  
collagen-­‐1,	  and	  counterstained	  with	  Hoescht	  3553	  nuclear	  stain.	  (b-­‐d)	  In	  day	  1	  cultures,	  
sNAG	  100ug/ml,	  10ug/ml	  and	  VEGF	  50ng/ml	  show	  increased	  collagen-­‐1	  deposition	  
compared	  to	  control.	  (f)	  By	  day	  3,	  VEGF	  50ng/ml	  was	  significantly	  augmented	  compared	  
to	  sNAG	  and	  control	  spheroids.	  












































Figure	  10:	  Induction	  of	  SMC	  markers	  by	  ADSCs	  in	  3-­‐day	  cell	  culture.	  Representative	  
images	  of	  whole-­‐mount	  heterotypic	  spheroids	  (72	  hours)	  labeled	  with	  antibodies	  
directed	  against	  anti-­‐hPECAM1,	  anti-­‐human	  aSMA,	  and	  counterstained	  with	  Hoescht	  
3553	  nuclear	  stain.	  sNAG	  100ug/ml	  spheroids	  show	  significantly	  increased	  aSMA	  
expression	  compared	  to	  VEGF	  50ng/ml	  and	  control.	  sNAG	  10ug/ml	  also	  displayed	  
increased	  aSMA	  expression,	  but	  was	  less	  abundant	  compared	  to	  sNAG	  100ug/ml.	  
	   	  
sNAG	  100	  ug/ml 
VEGF	  50ng/ml Control 



















Figure	  11:	  Heterotypic	  interactions	  during	  vascular	  spheroid	  formation	  in	  sNAG	  treated	  
cultures	  increased	  collagen	  type-­‐4	  deposition.	  (	  c,d	  and	  g,h)	  sNAG	  nanofibers	  augment	  
heterotypic	  cross-­‐talk	  and	  alignment	  between	  UCB-­‐EPCs	  and	  ADSC-­‐VSMCs.	  Images	  
reveal	  basement	  membrane	  deposition	  (white	  arrow	  heads)	  around	  developing	  
microvessels	  in	  sNAG	  100ug/ml	  treated	  tissues.	  These	  arrows	  also	  reveal	  the	  co-­‐
assocaition	  of	  these	  2	  cells	  at	  this	  location.	  (b,f)	  VEGF	  50ng/ml	  treated	  spheroids	  show	  
minimal	  cellular	  alignment	  with	  scant	  amounts	  of	  collagen	  type-­‐4	  deposition.	  (a,	  e)	  
Control	  spheroids	  did	  not	  express	  collagen	  type-­‐4	  and	  show	  no	  cellular	  alignment	  or	  
organization.	  





























Figure	  12:	  Recruitment	  of	  pericytes	  to	  the	  ablumenal	  surface	  of	  EC-­‐lined	  tubes	  within	  
vascular	  guidance	  tunnels.	  Heterotypic	  microtissue	  spheroids	  were	  allowed	  to	  assemble	  
for	  3	  days,	  fixed,	  and	  processed	  for	  immunofluorescence	  using	  confocal	  microscopy.	  
UCB-­‐EPCs	  were	  stained	  with	  endothelial	  specific	  marker,	  hPECAM1	  (red),	  whereas	  ADSC-­‐
VSMC	  were	  labeled	  with	  aSMA	  (green).	  sNAG	  100ug/ml	  treated	  spheroids	  show	  
association	  of	  pericytes	  with	  endothelial	  tubes	  on	  the	  abluminal	  surface	  (white	  arrows).	  
ECs	  form	  a	  continues	  layer	  with	  ADSC-­‐VSMCs	  recruited	  to	  the	  basal	  surface	  (White	  
arrows).	  Blue	  arrows	  indicate	  the	  border	  of	  the	  vascular	  guidance	  tunnel	  and	  the	  
entrance	  of	  ADSC-­‐VSMCs	  to	  these	  boarders.	  Basement	  membrane	  matrices	  were	  stained	  
with	  collagen	  IV	  (blue).	  Staining	  of	  aSMA	  (green)	  versus	  the	  col-­‐4	  (blue),	  reveals	  the	  
location	  of	  the	  pericytes	  in	  relation	  to	  the	  baseent	  membrane.	  This	  reveals	  a	  continuous	  
basement	  membrane	  (arrows)	  along	  the	  ablumenal	  surface	  of	  developing	  microvesssels	  
and	  between	  the	  perivascular	  cells	  and	  the	  endothelium.	  	  
	  
	   	  




Chapter	  5:	  DISCUSSION	  
CELL	  CULTURE	  
Adipose-­‐derived	  stem	  cells	  represent	  a	  promising	  source	  of	  autologous	  post-­‐
natal	  stem	  cells	  that	  have	  the	  advantage	  of	  ease	  of	  harvest,	  minimal	  discomfort	  to	  the	  
patient	  and	  high	  yield	  through	  percutaneous	  harvest.	  Like	  bone	  marrow	  and	  umbilical	  
cord	  mesenchymal	  stem	  cells,	  ADSCs	  are	  able	  to	  differentiate	  into	  cells	  of	  mesodermal	  
origin.	  Further,	  ADSCs	  can	  be	  cryopreserved	  then	  thawed	  without	  negatively	  impacting	  
their	  viability	  and	  plasticity.	  Compared	  to	  ES	  or	  iPS	  cells,	  ADSCs	  do	  not	  require	  genetic	  
reprogramming	  to	  induce	  pluripotency,	  reducing	  the	  likelihood	  of	  teratoma	  formation	  in	  
vivo.	  While	  ADSCs	  do	  not	  possess	  the	  broad	  plasticity	  of	  either	  ES	  or	  iPS	  cells,	  limited	  
mesodermal	  plasticity	  may	  prove	  more	  safe	  and	  suitable	  for	  differentiation	  of	  
mesodermal	  cell	  populations.	  Several	  groups	  have	  reported	  that	  ADSCs	  can	  be	  induced	  
to	  differentiate	  to	  SMCs	  or	  pericyte-­‐like	  cells	  in	  vitro	  by	  cytokines	  or	  chemical	  agents.	  	  In	  
the	  present	  study,	  we	  use	  a	  differentiation	  protocol	  that	  avoids	  the	  introduction	  of	  
transgenes	  or	  non-­‐specific	  reagents	  that	  may	  have	  unanticipated	  effects	  on	  the	  genome	  
of	  differentiated	  cells,	  providing	  greater	  opportunity	  for	  the	  introduction	  of	  ADSC-­‐
derived	  VSMCs	  to	  in	  vivo	  systems.	  	  
To	  demonstrate	  that	  ADSCs	  can	  be	  committed	  to	  the	  VSMC	  lineage	  using	  our	  
protocol,	  cells	  were	  grown	  in	  serum-­‐free	  ADSC	  medium	  supplemented	  with	  5.0	  ng/ml	  
TGF-­‐b1	  as	  previously	  described.	  After	  five	  days	  in	  our	  differentiation	  medium,	  ADSCs	  
exhibited	  smooth	  muscle	  cell	  morphology,	  including	  detectable	  contractile	  fibers,	  while	  
control	  ADSCs	  did	  not	  undergo	  VSMC	  differentiation.	  To	  further	  examine	  VSMC	  
characteristics	  of	  ADSC-­‐derived	  VSMCs,	  RT-­‐PCR	  and	  immunoblot	  analyses	  were	  
performed	  by	  the	  Visconti	  lab.	  Results	  show	  that	  both	  transcript	  and	  protein	  for	  early	  
markers	  of	  VSMC	  differentiation	  (aSMA	  and	  SM22)	  are	  detected	  first	  and	  their	  levels	  of	  
expression	  increase	  over	  time.	  Late	  VSMC	  markers	  (Calponin	  and	  SM-­‐MHC)	  are	  detected	  
later	  and	  in	  increasing	  amounts	  in	  differentiated	  cell	  populations.	  Importantly,	  this	  
temporo-­‐specific	  and	  increased	  expression	  of	  SMC	  markers	  is	  similar	  to	  that	  exhibited	  
by	  differentiating	  smooth	  muscle	  cells	  in	  vivo.	  	  
In	  support	  of	  previous	  RT-­‐PCR	  and	  immunoblot	  analyses,	  immunofluorescent	  
microscopic	  assays	  of	  these	  VSMC	  markers	  were	  also	  examined	  by	  the	  Visconti	  lab.	  
Results	  demonstrate	  that	  a	  limited	  number	  of	  ADSCs	  express	  early	  VSMC	  differentiation	  
markers	  (aSMA	  and	  SM22)	  while	  no	  detectable	  late	  differentiation	  markers	  were	  
observed.	  As	  time	  in	  differentiation	  culture	  increased,	  expression	  of	  early	  markers	  
increased	  and	  late	  markers	  are	  detected	  and	  also	  increased	  over	  time.	  These	  results	  
suggest	  that	  as	  ADSCs	  differentiate	  into	  VSMCs,	  their	  rate	  of	  proliferation	  decreases	  
compared	  to	  undifferentiated	  ADSCs.	  Collectively,	  these	  experiments	  provide	  strong	  
evidence	  that	  ADSCs	  are	  capable	  of	  being	  differentiated	  into	  the	  VSMC	  lineage	  and	  may	  
represent	  a	  suitable	  alternative	  cell	  source	  for	  vascular	  tissue	  engineering	  applications.	  	  
Another	  significant	  challenge	  in	  advancing	  prevascularization	  strategies	  in	  tissue	  
engineering	  is	  the	  lack	  of	  easily	  isolated	  autologous	  EC	  sources.	  The	  ability	  to	  isolate	  
late-­‐outgrowth	  EPCs	  noninvasively	  from	  peripheral	  blood	  and	  expand	  the	  colonies	  in	  
long-­‐term	  cultures	  is	  a	  major	  development	  for	  autologous	  cell	  therapies.	  Late-­‐
outgrowth	  EPCs	  have	  been	  pursued	  as	  an	  alternative	  cell	  source	  for	  tissue	  engineering	  
strategies.	  The	  two	  to	  three	  week	  time	  interval	  before	  EPC	  colonies	  are	  observed	  is	  a	  
clinical	  drawback	  for	  emergency	  interventions,	  but	  the	  cells	  are	  highly	  proliferative,	  
capable	  of	  undergoing	  more	  than	  30	  population	  doubling	  while	  maintaining	  a	  stable	  EC	  
phenotype	  during	  long-­‐term	  culture,	  justifying	  their	  use	  for	  cellular	  therapies.	  
To	  establish	  procedures	  for	  the	  generation	  prevascularized	  microtissue	  
spheroids,	  we	  employed	  similar	  techniques	  that	  have	  been	  developed	  for	  the	  
generation	  of	  tumor	  cell	  spheroids.	  We	  seeded	  EC	  suspension	  into	  non-­‐adherent	  
micromolds,	  which	  led	  to	  the	  formation	  of	  uniform	  microtissue	  aggregates	  within	  24	  
hours.	  The	  initial	  series	  of	  experiments	  we	  performed	  were	  to	  compare	  the	  phenotypic	  
characteristics	  of	  late-­‐outgrowth	  UCB-­‐EPCs	  to	  early-­‐outgrowth	  UCB-­‐EPCs	  and	  mature	  
hMVEC-­‐Cs	  when	  grown	  under	  identical	  culture	  conditions	  in	  our	  3D	  microtissue	  
spheroid	  model.	  Panendothelial	  marker	  hPECAM-­‐1	  expression	  was	  used	  as	  a	  sign	  of	  EC	  
maturation	  and	  visualized	  using	  confocal	  microscopy.	  Results	  show	  intermittent	  
hPECAM-­‐1	  expression	  throughout	  the	  spheroid	  in	  early-­‐outgrowth	  UCB-­‐EPC	  and	  ECs	  
failed	  to	  differentiate	  into	  a	  surface	  monolayer	  as	  compared	  to	  late-­‐outgrowth	  UCB-­‐
EPCs	  and	  hMVEC-­‐Cs.	  Next,	  we	  examined	  whether	  inherent	  differences	  in	  hPECAM-­‐1	  
expression	  existed	  between	  late-­‐outgrowth	  UCB-­‐EPCs	  and	  hMVEC-­‐Cs;	  and	  found	  that	  
UCB-­‐EPCs	  and	  hMVECs	  have	  comparable	  levels	  of	  hPECAM-­‐1	  expression.	  This	  is	  
indicative	  of	  their	  maturation	  state,	  as	  these	  markers	  are	  typically	  associated	  with	  a	  
more	  mature	  endothelial	  phenotype.	  Overall,	  these	  results	  suggest	  that	  UCB-­‐EPCs	  were	  
successfully	  differentiated	  into	  a	  mature	  EC	  phenotype	  in	  our	  optimized	  3D	  microtissue	  
spheroid	  model	  and	  that	  they	  may	  be	  a	  suitable	  alternative	  cell	  source	  for	  tissue	  
engineering	  applications.	  	  
The	  nanofiber	  method	  has	  advantages	  over	  conventional	  suspension	  culture	  
methods	  for	  anchorage-­‐dependent	  cells.	  As	  compared	  to	  conventional	  spheroid	  culture,	  
nanofiber	  supplemented	  suspension	  cultures	  can	  improve	  spheroid	  formation	  efficiency	  
and	  possibly	  cell	  viability.	  In	  contrast	  to	  microcarrier	  cultures,	  in	  which	  the	  shear	  stress	  
could	  damage	  cells	  cultured	  on	  the	  microcarrier	  surface,	  the	  cells	  inside	  of	  the	  spheroids	  
are	  protected	  from	  shear	  damage	  in	  nanofiber-­‐supplemented	  suspension	  culture.	  
Because	  the	  nanofiber	  material	  is	  poly-­‐N-­‐acetyl	  glucosamine,	  which	  are	  biocompatible	  
and	  biodegradable,	  cells	  cultured	  with	  sNAG	  nanofibers	  can	  be	  transplanted	  into	  
patients	  for	  therapeutic	  purposes	  without	  the	  removal	  of	  the	  sNAG	  nanofibers	  prior	  to	  
cell	  transplantation.	  	  
	  
SPECIFIC	  AIM-­‐1	  
The	  goal	  of	  the	  first	  aim	  was	  to	  gain	  preliminary	  insights	  into	  the	  effects	  of	  sNAG	  
nanofibers	  on	  UCB-­‐EPC	  and	  hMVEC-­‐C	  microtissue	  spheroid	  assembly	  and	  function	  in	  
vitro	  under	  both	  2D	  and	  3D	  culture	  conditions.	  In	  particular,	  the	  biological	  response	  of	  
endothelial	  cells	  to	  the	  instructive	  topography	  of	  sNAG	  nanofiber	  matrices	  was	  
investigated	  by	  analyzing	  EC	  phenotype	  and	  morphology	  using	  bright	  field	  and	  confocal	  
microscopy.	  
In	  general,	  the	  dynamic	  state,	  functions,	  and	  phenotype	  of	  ECs	  are	  regulated	  by	  
highly	  complex	  temporal	  and	  spatial	  coordination	  of	  cell-­‐cell	  and	  cell-­‐substrate	  
interactions	  detected	  by	  cell	  receptors	  and	  integrated	  by	  cellular	  signaling	  pathways.	  	  
Many	  of	  these	  events	  are	  mediated	  via	  cell	  adhesion	  proteins	  that	  form	  bonds	  with	  the	  
cell’s	  surface	  integrins,	  specifically	  a5b1	  and	  aVb3,	  which	  induce	  firm	  adhesion	  at	  the	  
cell-­‐substrate	  interface.	  In	  previous	  studies,	  sNAG	  nanofibers	  have	  been	  shown	  to	  up-­‐
regulate	  a5b1	  and	  aVb3	  expression	  in	  ECs,	  which	  activates	  a	  series	  of	  downstream	  
signaling	  pathways,	  including	  a	  Rac-­‐dependent	  pathway	  generally	  thought	  to	  result	  in	  
migration,	  MAP	  kinase	  (proliferation),	  PI3K/Akt	  (survival)	  and	  IKK/NFkB	  (survival).	  
Although	  the	  exact	  mechanism	  by	  which	  sNAG	  nanofibers	  effect	  ECs	  in	  vitro	  is	  unknown,	  
many	  of	  these	  pathways	  are	  known	  to	  be	  mediated	  through	  integrin	  dependent	  
outside-­‐in	  signal	  transduction.	  Therefore,	  to	  further	  investigate	  the	  effects	  of	  sNAG	  
nanofibers	  on	  UCB-­‐EPCs	  function	  in	  vitro,	  we	  tested	  the	  hypothesis	  that	  sNAG	  nanofiber	  
topographies	  would	  provide	  an	  optimal	  or	  instructive	  interface	  for	  inducing	  UCB-­‐EPC	  
differentiation	  and	  will	  enhance	  assembly	  into	  tube-­‐like	  structures	  in	  vitro.	  	  
To	  test	  this	  hypothesis,	  2D	  Matrigel	  tube	  formation	  assays	  were	  performed.	  
Qualitative	  analysis	  of	  UCB-­‐EPCs	  show	  cellular	  adherence	  and	  spreading	  over	  the	  
surface	  of	  sNAG	  10ug/ml	  and	  100ug/ml	  treated	  Matrigel	  cultures.	  Quantitative	  analysis	  
of	  sprout	  and	  branch	  points	  support	  these	  observations.	  Results	  show	  a	  significant	  
increase	  in	  sprout	  formation	  in	  sNAG	  10	  ug/ml	  treated	  cultures	  compared	  to	  50ng/ml	  
VEGF,	  suggesting	  a	  robust	  angiogenic	  EC	  response	  to	  sNAG	  nanofiber	  topographic	  cues.	  
Additionally,	  sNAG	  100	  ug/ml	  treated	  cultures	  demonstrated	  a	  strong	  trend	  in	  the	  
formation	  of	  branching	  capillary-­‐like	  networks,	  suggesting	  a	  high	  degree	  of	  EC	  network	  
remodeling	  after	  only	  7	  hours.	  Results	  of	  this	  assay	  demonstrate	  that	  by	  varying	  the	  
culture	  concentrations	  of	  sNAG	  nanofibers,	  ECs	  will	  undergo	  a	  differential	  response	  to	  
the	  formation	  of	  tube-­‐like	  networks.	  This	  effect	  may	  be	  due	  to	  the	  temporo-­‐specific	  
preference	  of	  ECs	  to	  different	  surface	  topography’s	  during	  this	  dynamic	  process.	  
However,	  it	  is	  unclear	  whether	  the	  effect	  of	  sNAG	  nanofibers	  on	  EC	  morphology	  during	  
tube-­‐like	  network	  formation	  is	  the	  result	  of	  increased	  rigidity	  of	  the	  Matrigel	  gels,	  
whether	  it	  is	  due	  to	  increased	  a5b1	  and	  aVb3	  presentation	  (adhesion),	  or	  whether	  it	  is	  
due	  cellular	  dimensionality	  (i.e.	  2D	  versus	  3D	  culture).	  More	  studies	  are	  needed	  to	  
elucidate	  the	  specific	  sNAG	  matrix	  parameters	  that	  mediate	  EC	  morphogenesis	  in	  this	  
assay.	  	  
Three-­‐dimensional	  cell	  culture	  systems	  have	  gained	  increasing	  interest	  in	  drug	  
discovery	  and	  tissue	  engineering	  due	  to	  their	  evident	  advantages	  in	  providing	  more	  
physiologically	  relevant	  information	  and	  more	  predictive	  data	  for	  in	  vivo	  tests.	  Although	  
our	  2D	  Matrigel	  assay	  mentioned	  above	  provided	  valuable	  information	  regarding	  the	  
effects	  of	  sNAG	  on	  EC	  tube-­‐like	  network	  formation	  and	  function,	  2D	  cell	  culture	  tests	  are	  
limited	  in	  that	  they	  sometimes	  provide	  misleading	  and	  non-­‐predictive	  data	  for	  in	  vivo	  
responses.	  We,	  thus,	  developed	  a	  3D	  culture	  system	  to	  study	  the	  effects	  of	  sNAG	  
nanofibers	  on	  EC	  assembly	  and	  function	  in	  homotypic	  spheroid	  microtissues.	  We	  
hypothesized	  that	  the	  addition	  of	  sNAG	  nanofiber	  substrates	  to	  suspension	  cultures	  of	  
anchorage-­‐dependent	  UCB-­‐EPCs,	  it	  would	  promote	  spheroid	  formation	  by	  enhancing	  
cellular	  adhesion	  in	  addition	  to	  cell-­‐cell	  interactions.	  	  
hPECAM-­‐1	  is	  a	  membrane	  glycoprotein	  found	  at	  endothelial	  intercellular	  
junctions	  and	  has	  been	  shown	  to	  mediate	  cell-­‐cell	  interactions.	  In	  this	  study,	  the	  
morphology	  of	  attached	  ECs	  is	  considered	  to	  be	  an	  indication	  of	  cell	  adhesion	  with	  
spread	  morphology	  indicating	  greater	  adhesion	  than	  round	  morphology.	  hPECAM-­‐1	  
expression	  by	  endothelial	  cells	  was	  characterized	  using	  immunofluorescence	  confocal	  
microscopy	  in	  cross-­‐section	  and	  whole-­‐mount	  microtissue	  spheroids.	  Results	  suggest	  
that	  ECs	  in	  sNAG	  10ug/ml	  microtissue	  spheroids	  provided	  the	  optimal	  concentration	  of	  
nanofibers	  to	  induce	  cell	  migration	  toward	  the	  outer	  periphery	  of	  the	  modules.	  In	  
contrast,	  sNAG	  100ug/ml	  treated	  spheroids	  impeded	  cell	  migratory	  events,	  possibly	  due	  
to	  phenomenon	  of	  durotaxis.	  Once	  ECs	  migrated	  toward	  the	  outer	  surface	  of	  the	  
microtissue	  spheroids,	  ECs	  established	  a	  polarized	  elongated	  continuous	  monolayer	  
after	  1	  day	  in	  cell	  culture.	  This	  is	  evidenced	  by	  increased	  hPECAM-­‐1	  expression	  intensity,	  
which	  is	  indicative	  of	  a	  differentiated	  EC	  phenotype.	  Importantly,	  the	  differentiation	  
characteristics	  of	  this	  surface	  monolayer	  go	  beyond	  the	  degree	  of	  differentiation	  that	  
was	  obtained	  in	  our	  2D	  Matrigel	  culture.	  	  
In	  conclusion,	  the	  addition	  of	  nanofiber	  fragments	  to	  suspension	  cultures	  of	  
anchorage	  dependent	  ECs	  promoted	  spheroid	  formation.	  Spheroid	  formation	  in	  culture	  
without	  nanofibers	  may	  be	  mediated	  by	  interactions	  among	  cadherins	  on	  adjacent	  cells.	  
In	  contrast,	  in	  nanofiber	  supplemented	  culture,	  spheroid	  formation	  is	  also	  mediated	  by	  
cell	  binding	  to	  the	  nanofibers.	  In	  this	  case,	  it	  is	  possible	  that	  vitronectin	  (aVb3	  receptor)	  
and	  fibronectin	  (a5b1	  receptor)	  from	  the	  serum	  added	  to	  the	  culture	  medium	  are	  
absorbed	  on	  the	  nanofibers,	  and	  then	  the	  cells	  adhere	  to	  these	  nanofibers,	  thereby	  
forming	  spheroids.	  The	  higher	  efficiency	  of	  spheroid	  formation	  in	  nanofiber-­‐
supplemented	  culture	  may	  be	  due	  to	  the	  enhancement	  of	  EC	  assembly	  by	  nanofibers.	  
The	  conclusions	  in	  this	  aim	  are	  supported	  by	  (a)	  the	  observed	  polarized	  expression	  of	  
endothelial	  cell	  surface	  molecules	  (basal	  and	  lateral	  expression	  of	  h-­‐PECAM1	  at	  the	  
microtissue	  spheroid	  periphery),	  and	  (b)	  the	  ultrastructural	  characteristics	  of	  the	  surface	  
monolayer	  with	  well-­‐developed	  cell-­‐cell	  contacts,	  and	  (c)	  assembly	  and	  alignment	  of	  ECs	  
into	  primitive	  vessel-­‐like	  structures	  in	  sNAG	  treated	  3D	  cultures.	  Future	  studies	  will	  need	  
to	  focus	  on	  analyzing	  the	  effects	  of	  sNAG	  nanofibers	  in	  both	  2D	  and	  3D	  environments	  
and	  determining	  spheroid	  permeability	  in	  order	  to	  gain	  a	  better	  understanding	  of	  sNAG	  
nanofiber	  influence	  on	  EC	  cell-­‐cell	  junction	  formation.	  
	  
Specific	  Aim-­‐2	  
In	  the	  second	  aim,	  we	  focused	  not	  only	  on	  the	  initial	  assembly	  of	  vascular	  
spheroids,	  but	  on	  the	  expansion	  and	  stabilization	  of	  these	  modules	  to	  include	  robust	  
vascular	  networks.	  To	  do	  this,	  we	  tested	  whether	  sNAG	  nanofibers	  induced	  physiologic	  
alignment	  and	  organization	  of	  vascular	  cell	  types,	  whether	  sNAG	  nanofibers	  facilitated	  
recruitment	  of	  mural	  cells	  to	  nascent	  vascular	  structures,	  and	  whether	  sNAG	  nanofibers	  
augmented	  vessel	  stabilization	  via	  synthesis	  and	  deposition	  of	  basement	  membrane	  
proteins.	  We	  hypothesized	  that	  sNAG	  nanofibers	  would	  enhance	  vascular	  spheroid	  
formation	  via	  heterotypic	  interactions	  between	  vascular	  cell	  types	  leading	  to	  the	  
assembly	  of	  a	  mature	  and	  stabilized	  vascular	  network.	  	  	  
Previous	  experiments	  performed	  in	  aim-­‐1	  demonstrated	  that	  UCB-­‐EPCs	  treated	  
with	  sNAG	  nanofibers	  enhanced	  cell-­‐cell	  junction	  formation	  and	  clustering	  of	  ECs	  into	  
what	  appeared	  to	  be	  primitive	  vascular	  networks.	  The	  present	  study	  confirmed	  previous	  
observations	  that	  EC-­‐only	  cultures	  demonstrate	  limited	  vascular	  network	  formation.	  The	  
combination	  of	  UCB-­‐EPCs	  and	  ADSC-­‐VSMCs	  with	  sNAG	  nanofibers	  led	  to	  the	  
development	  of	  remarkably	  complex	  vascular	  networks	  with	  a	  wide	  range	  of	  vessel	  
geometries.	  These	  observations	  supported	  our	  theory	  that	  ADSC-­‐VSMCs	  are	  able	  to	  
behave	  as	  pericyte-­‐like	  cells	  in	  our	  microtissue	  spheroid	  model	  by	  engaging	  in	  molecular	  
cross-­‐talk	  with	  ECs	  to	  induce	  vascular	  network	  formation.	  Furthermore,	  we	  found	  that	  
aSMA	  antigen	  expression	  by	  ADSC-­‐VSMCs	  was	  upregulated	  by	  day	  3	  in	  sNAG	  treated	  
cultures,	  but	  the	  factors	  responsible	  for	  this	  effect	  were	  undefined.	  Heterotypic	  
microtissue	  spheroids	  show	  that	  ADSC-­‐VSMCs	  that	  were	  adjacent	  to	  UCB-­‐EPCs	  
specifically	  displayed	  induction	  of	  aSMA	  expression	  and	  its	  organization	  into	  contractile	  
fibers.	  Thus,	  initial	  experiments	  suggest	  that	  sNAG	  nanofiber	  topography	  has	  an	  effect	  
on	  EC	  assembly	  into	  vascular	  tubes	  and	  ADSC-­‐VSMC	  differentiation	  over	  time.	  	  
When	  ECM	  protein	  expression	  and	  deposition	  were	  examined,	  we	  observed	  
striking	  differences	  between	  control	  and	  sNAG	  treated	  microtissue	  spheroids.	  Among	  
the	  large	  number	  of	  possible	  target	  for	  analysis	  of	  ECM	  proteins,	  we	  chose	  well-­‐
documented	  and	  essential	  components	  of	  the	  vascular	  wall	  ECM:	  collagen	  types	  I	  and	  
IV.	  We	  note	  that	  our	  findings	  center	  on	  the	  deposition	  and	  structural	  organization	  of	  
ECM	  proteins	  as	  they	  relate	  to	  vascular	  tissue	  engineering.	  As	  such,	  our	  primary	  means	  
of	  analysis	  was	  immunofluorescence	  as	  it	  is	  the	  most	  reliable	  method	  to	  document,	  
quantify,	  and	  distinguish	  proteins.	  This	  approach	  has	  been	  widely	  utilized	  in	  the	  analysis	  
of	  ECM	  deposition.	  
Results	  show	  that	  collagen	  type-­‐1	  in	  sNAG	  nanofiber	  treated	  cultures	  was	  up-­‐
regulated	  in	  day-­‐1	  cultures	  compared	  to	  controls.	  However,	  by	  day-­‐3	  sNAG	  treated	  
microtissue	  spheroids,	  a	  significant	  reduction	  of	  collagen	  type-­‐1	  was	  observed.	  One	  
possibility	  for	  this	  finding	  is	  that	  collagen	  I	  is	  known	  to	  be	  produced	  by	  cells	  undergoing	  
angiogenesis,	  which	  could	  have	  been	  halted	  by	  day	  3	  cultures	  reminiscent	  of	  a	  quiescent	  
EC	  phenotype.	  Another	  possibility	  is	  that	  vascular	  collagen	  I	  may	  primarily	  be	  produced	  
by	  synthetic	  SMCs,	  which	  could	  have	  retained	  a	  contractile	  phenotype	  by	  day	  3.	  This	  
possibility	  is	  further	  supported	  by	  the	  previous	  experiment	  where	  aSMA	  expression	  in	  
sNAG	  treated	  cultures	  was	  up-­‐regulated	  in	  day	  3	  cultures.	  Overall,	  these	  studies	  suggest	  
that	  sNAG	  nanofibers	  have	  an	  effect	  on	  spheroid	  maturation	  events	  leading	  to	  variable	  
production	  of	  collagen	  type	  1.	  	  
Furthermore,	  we	  show	  that	  sNAG	  nanofibers	  mediate	  vascular	  morphogenesis	  
leading	  to	  EC	  tube	  and	  vascular	  guidance	  tunnel	  formation.	  Vascular	  guidance	  tunnels	  
serve	  as	  a	  critical	  matrix	  conduit	  for	  the	  recruitment	  and	  migration	  of	  pericytes	  along	  
the	  abluminal	  surface	  of	  EC-­‐lined	  tubes.	  In	  turn,	  these	  dynamic	  events	  resulted	  in	  
continuous	  deposition	  of	  EC	  basement	  membrane	  proteins	  (i.e.	  collagen	  type-­‐4).	  This	  
process	  is	  a	  necessary	  step	  in	  the	  progression	  of	  tube	  assembly	  toward	  maturation	  and	  
stabilization.	  Because	  pericyte	  coverage	  of	  EC	  tubes	  is	  more	  abundant	  in	  sNAG	  
100ug/ml	  cultures,	  this	  may	  represent	  the	  optimal	  concentration	  for	  assembly	  of	  
prevascularized	  microtissue	  spheroids.	  Thus,	  it	  is	  likely	  that	  sNAG	  mediated	  EC-­‐pericyte	  
interactions,	  which	  catalyze	  vascular	  basement	  membrane	  matrix	  assembly,	  establish	  a	  
matrix	  microenvironment	  that	  anchors	  and	  spatially	  organizes	  these	  cells	  into	  functional	  
structures.	  sNAG	  modified	  microtissue	  spheroids	  therefore	  lead	  to	  unique	  EC	  and	  
pericyte	  signaling	  events	  that	  are	  necessary	  for	  vascular	  tube	  maturation	  and	  
stabilization.	  
In	  conclusion,	  the	  addition	  of	  sNAG	  nanofiber	  fragments	  to	  3D	  micro-­‐mold	  
cultures	  of	  EC-­‐ADSC-­‐VSMCs	  promoted	  spheroid	  formation.	  Our	  data	  suggest	  that	  EC-­‐
pericyte	  interactions	  are	  necessary	  for	  vascular	  tube	  assembly,	  maturation	  and	  
stabilization	  in	  sNAG	  treated	  microtissue	  spheroids	  through	  basement	  membrane	  
remodeling	  events,	  and	  through	  key	  changes	  in	  EC	  and	  pericyte	  integrin	  expression	  that	  
facilitate	  recognition	  of	  these	  nanofibers.	  These	  changes	  most	  likely	  act	  in	  conjunction	  
with	  growth	  factor-­‐signaling	  pathways,	  mediated	  by	  sNAG	  nanofibers,	  to	  provide	  unique	  
signals	  that	  are	  necessary	  for	  the	  transition	  from	  vascular	  tube	  morphogenesis	  to	  
stabilization.	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